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ABSTRACT 
Background 
Statins are drugs of known efficacy in the treatment of hypercholesterolaemia. However, 
statin-induced myopathy, an adverse effect of statins in up to 15% of its users, has warranted 
a reduction in the prescription dose or discontinuation of the drug. The exact mechanism of 
statin-induced myopathy is unknown, but the potential of Coenzyme Q10 (CoQ10) as 
treatment has been recognized due to decreased human plasma CoQ10 levels found after 
statin use and the concomitant role of CoQ10 in muscle function. 
Objectives 
This systematic review assessed the effect of CoQ10 supplementation on: the severity of 
statin-induced myopathic symptoms, levels of plasma creatine kinase, intramuscular and 
plasma CoQ10, as well as whether any adverse effects of CoQ10 supplementation such as 
abdominal pain, nausea and vomiting or headaches were experienced. 
Search methods 
Two searches for studies were conducted in The Cochrane Central Register of Controlled 
Trials (inception to March 2011 and inception to November 2011), MEDLINE (inception to 
March 2011 and inception to November 2011), Web of Science (inception to March 2011 and 
inception to November 2011), Science Direct (inception to March 2011 and inception to 
February 2012), Wiley Online Library (inception to March 2011 and inception to February 
2012), Springerlink (inception to April 2011 and inception to February 2012), EBSCOhost 
[Academic Search Premier and CAB abstracts (inception to March 2011 and inception to 
February 2012), CINAHL (inception to March 2011 and inception to November 2011)],  
Scopus (inception to March 2011 and inception to November 2011) and Google Scholar 
(inception to March 2011 and inception to February 2012). Reference lists of articles were 
hand searched for relevant clinical trials. Only trials with a full text were included in the review. 
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Selection criteria   
Randomised controlled trials (RCTs) were included with adult participants (mean of 18-64.99 
years) of all race/ethnic groups and gender on statin therapy with reported myopathic 
symptoms from an unknown cause. The intervention was in the form of a pure oral 
supplement of CoQ10 irrespective of dose, duration and frequency, and the control in the 
form of a placebo, a similar antioxidant, or no intervention. Outcomes included the severity of 
myopathic symptoms, levels of plasma creatine kinase (U/L), intramuscular CoQ10 (µmol/kg) 
and plasma CoQ10 (µmol/L), as well as adverse effects of CoQ10. 
Data collection and analysis   
The principle investigator and one independent reviewer selected the studies, extracted data 
and assessed for risk of bias using the Cochrane Collaboration‘s tool for assessing risk of 
bias. Authors of relevant clinical trials were contacted for additional information. 
Results   
Two RCTs were included in the review, totaling 76 participants. A meta-analysis could not be 
performed, thus the review is narrative. There were an insufficient number of RCTs to confirm 
whether routine supplementation of CoQ10 improves statin-induced myopathic symptoms.  
Conclusions  
More and larger RCTs are required to determine the efficacy of CoQ10 supplementation in 
statin-induced myopathy. Consensus needs to be reached regarding the definition and 
measurement instrument/s of myopathy so that results of future studies can easily be 
compared and synthesized.  
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OPSOMMING 
Agtergrond 
Statiene is medikasie bekend vir die effektiewe behandeling van hipercholesterolemie. 
Statien-geïnduseerde miopatie is egter ‗n newe-effek wat voorkom in tot 15% van gebruikers, 
wat ‗n vermindering in die voorgeskrewe dosis of staking van die medikasie tot gevolg het. 
Die presiese meganisme van statien-geïnduseerde miopatie is onbekend, maar die 
potensiaal van Koënsiem Q10 (CoQ10) is geïdentifiseer as ‗n moontlike behandeling 
aangesien menslike plasma CoQ10 vlakke verlaag na die gebruik van statiene en as gevolg 
van die rol van CoQ10 in spierfunksie.  
Doelwitte 
Hierdie sistematiese literatuuroorsig het die effek van CoQ10 supplementasie bepaal op: die 
graad van statien-geïnduseerde miopatiese simptome, plasma kreatien kinase vlakke, intra-
muskulêre en plasma CoQ10 vlakke, asook die teenwoordigheid van enige newe-effekte van 
CoQ10 supplementasie soos abdominale pyn, naarheid en braking of hoofpyne. 
Soektogstrategie 
Twee soektogte vir studies is uitgevoer in The Cochrane Central Register of Controlled Trials 
(ontstaan tot Maart 2011 en ontstaan tot November 2011), MEDLINE (ontstaan tot Maart 
2011 en ontstaan tot November 2011), Web of Science (ontstaan tot Maart 2011 en ontstaan 
tot November 2011), Science Direct (ontstaan tot Maart 2011 en ontstaan tot Februarie 
2012), Wiley Online Library (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), 
Springerlink (ontstaan tot April 2011 en ontstaan tot Februarie 2012), EBSCOhost [Academic 
Search Premier en CAB abstracts (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), 
CINAHL (ontstaan tot Maart 2011 en ontstaan tot November 2011)],  Scopus (ontstaan tot 
Maart 2011 en ontstaan tot November 2011) en Google Scholar (ontstaan tot Maart 2011 en 
ontstaan tot Februarie 2012). Verwysingslyste van artikels is ook met die hand nagegaan vir 
relevante kliniese proewe. Slegs kliniese proewe waarvan die volteks beskikbaar was, is 
ingesluit in die oorsig.  
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Seleksiekriteria  
Ewekansige gekontroleerde proewe (EGP) is ingesluit met volwasse deelnemers (gemiddeld 
18-64.99 jaar) van alle rasse/etniese groepe en geslag op statien-terapie met gerapporteerde 
miopatie simptome van onbekende oorsaak. Die intervensie was ‗n suiwer orale supplement 
van CoQ10 ongeag die dosis, duurte en frekwensie, en die kontrole ‗n plasebo, soortgelyke 
antioksidant, of geen intervensie. Uitkomste het ingesluit: die graad van miopatie simptome, 
vlakke van plasma kreatien kinase (U/L), intra-muskulêre CoQ10 (µmol/kg) en plasma CoQ10 
(µmol/L), sowelas newe-effekte van CoQ10. 
Dataversameling en -analise 
Die hoof ondersoeker en een onafhanklike hersiener het die seleksie van studies en data-
ekstraksie onderneem en die risiko vir sydigheid geassesseer deur gebruik te maak van die 
Cochrane Collaboration’s tool for assessing risk of bias. Outeurs van relevante kliniese 
proewe is geraadpleeg vir addisionele inligting 
Resultate   
Twee EGP is ingesluit in die oorsig met ‗n totaal van 76 deelnemers. ‗n Meta-analise kon nie 
uitgevoer word nie, dus is die oorsig beskrywend. Daar was te min EGP om te bewys dat 
roetine supplementasie van CoQ10 statien-geïnduseerde miopatiese simptome verbeter. 
Gevolgtrekkings 
Meer en groter EGP is nodig om die effektiwiteit van CoQ10 supplementasie in statien-
geïnduseerde miopatie te bepaal. Konsensus moet bereik word ten opsigte van die definisie 
en metingsinstrument/e van miopatie sodat die resultate van toekomstige studies makliker 
vergelyk en verwerk kan word. 
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LIST OF DEFINITIONS 
MEDICAL  
Acute Renal Failure: “Renal failure of sudden onset, such as from physical trauma, 
infection, inflammation, or toxicity. Symptoms include uremia and usually oliguria or anuria, 
with hyperkalemia and pulmonary edema. Three types are distinguished: prerenal, associated 
with poor systemic perfusion and decreased renal blood flow, such as with hypovolemic 
shock or congestive heart failure; intrarenal, associated with disease of the renal 
parenchyma, such as tubulointerstitial nephritis, acute interstitial nephritis, or nephrotoxicity; 
and postrenal, resulting from obstruction of urine flow out of the kidneys.‖ 1 
Amyotrophic Lateral Sclerosis: “A progressive neurological disorder characterized by loss 
of connection and death of motor neurons in the cortex and spinal cord.‖ 2 
Coronary Artery Disease: “An abnormal condition that may affect the heart‘s arteries and 
produce various pathologic effects, especially the reduced flow of oxygen and nutrients to the 
myocardium. The most common kind of coronary artery disease is coronary atherosclerosis, 
now the leading cause of death in the Western world. Other coronary artery diseases include 
coronary arteritis and fibromuscular hyperplasia of the coronary arteries. Also called coronary 
heart disease.‖ 3 
Cardiovascular Disease: “Any abnormal condition characterized by dysfunction of the heart 
and blood vessels. In the United States, cardiovascular disease is the leading cause of death. 
Some common kinds of cardiovascular disease are atherosclerosis, myocardiopathy, 
rheumatic heart disease, syphilitic endocarditis, and systemic venous hypertension.‖ 4 
Diabetes Mellitus: ―A condition characterised by a raised concentration of glucose in the 
blood due to a deficiency in the production and/or action of INSULIN, a hormone made in 
special cells in the pancreas called the islet cells of Langerhans. It is one of the world's most 
serious health problems.‖ 5 
Huntington’s disease [after George S. Huntington, American physician, 1851–1916]: ―A rare 
abnormal hereditary condition characterized by chronic progressive chorea and mental 
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deterioration that results in dementia. An individual afflicted with the condition usually shows 
the first signs in the fourth decade of life and dies within 15 years. It is transmitted as an 
autosomal trait and becomes progressively worse in severity as the trinucleotide repeats grow 
in successive generations. There is no known effective treatment, but symptoms can be 
relieved with medication.‖ 6 
Hypertrophic Cardiomyopathy: “An abnormal condition characterized by gross hypertrophy 
of the interventricular septum and left ventricular free wall of the heart. Ventricular 
hypertrophy results in impaired diastolic filling and reduced cardiac output. Signs and 
symptoms, such as fatigue and syncope, are often associated with exercise when the 
demand for increased cardiac output cannot be met. This is commonly a genetic disease, with 
numerous genes implicated. Also called hypertrophic obstructive cardiomyopathy.‖ 7 
Hypothyroidism: “A condition characterized by decreased activity of the thyroid gland. It 
may be caused by surgical removal of all or part of the gland, over dosage with antithyroid 
medication, decreased effect of thyroid-releasing hormone secreted by the hypothalamus, 
decreased secretion of thyroid-stimulating hormone by the pituitary gland, atrophy of the 
thyroid gland itself, or peripheral resistance to thyroid hormone.‖ 8 
Idiopathic Infertility: “Idiopathic is a term applied to diseases to indicate that their cause is 
unknown. Infertility is the inability to conceive or induce conception.‖ 9,10 
Lipophilic: “The ability to dissolve or attach to lipids.‖ 11 
Lymphatic System: “A vast, complex network of capillaries, thin vessels, valves, ducts, 
nodes, and organs that helps protect and maintain the internal fluid environment of the entire 
body by producing, filtering, and conveying lymph and producing various blood cells.‖ 12 
Mitochondria: “Specialized organelles of all eukaryotic cells that use oxygen. Often called 
the powerhouses of the cell, mitochondria are responsible for energy generation by the 
process of oxidative phosphorylation.‖ 13 
Mitochondrial Cytopathy: “A diverse group of disorders characterized by decreased energy 
production by the mitochondria; they may be acquired or secondary to another disorder such 
Stellenbosch University http://scholar.sun.ac.za
  xxi 
as hyperthyroidism or result from heritable defects in the mitochondrial genome. Symptoms 
develop gradually and manifestations are extremely variable and often resemble those of 
other diseases, affecting the muscles, central and peripheral nervous systems, eyes, ears, 
heart, kidneys, liver, and pancreas.‖ 14 
Multiple Sclerosis: “A disorder of the central nervous system caused by damage of the 
myelin sheath. Symptoms include pain, weakness, numbness, tingling, paralysis, tremors, 
and muscle dysfunction.‖ 15 
Parkinson’s Disease [after James Parkinson]: ―A slowly progressive degenerative neurologic 
disorder characterized by resting tremor, pill rolling of the fingers, a mask-like facies, shuffling 
gait, forward flexion of the trunk, loss of postural reflexes, and muscle rigidity and weakness.‖ 
16 
STASTISTICAL 
Blinded: “Within a clinical trial, hiding the knowledge of a particular treatment. The three 
types of blinding are the following: observer-blind—when the researcher does not know the 
particular treatment that a patient undergoes; single-blind, when only the patient does not 
know to which group he or she belongs; and double-blind, when both the patient and the one 
providing the treatment do not know group identity. These types of blinding ensure—all other 
factors being identical—that any observed results are not the result of bias of the study 
participants.‖ 17 
Confidence Interval: “An interval which has a specified probability of containing a given 
parameter or characteristic.‖ 18 
Forest Plot: “Plot that displays effect estimates and confidence intervals for both individual 
studies and meta-analyses.‖ 19 
Funnel Plot: “A possible strategy to detect potential publication bias. A funnel plot is a 
scatterplot of sample size versus estimated effect size for all included studies in a meta-
analysis. If the plot obtained does not resemble the shape of a funnel, then the possibility of a 
publication bias is considered highly likely.‖ 20 
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Heterogeneity: “Variability in the intervention effects being evaluated in the different studies 
is known as statistical heterogeneity, and is a consequence of clinical or methodological 
diversity, or both, among the studies.‖ 21 
Meta-Analysis: “The use of statistical methods to summarise the results of independent 
studies.‖ 22 
Narrative Review: “Subjective (rather than statistical) methods for reviews where meta-
analysis is either not feasible or not sensible.‖ 23  
Randomised Controlled Trial: “A clinical trial in which the subjects are randomly distributed 
into groups which are either subjected to the experimental procedure (as use of a drug) or 
which serve as controls.‖ 24 
Risk of Bias: “Bias is a systematic error or deviation in results or inferences from the truth. In 
studies of the effects of health care, the main types of bias arise from systematic differences 
in the groups that are compared (selection bias), the care that is provided, exposure to other 
factors apart from the intervention of interest (performance bias), withdrawals or exclusions of 
people entered into a study (attrition bias) or how outcomes are assessed (detection bias). 
Reviews of studies may also be particularly affected by reporting bias, where a biased subset 
of all the relevant data is available.‖ 25 
Systematic Review: “A systematic review is a review that attempts to collate all empirical 
evidence that fits pre-specified eligibility criteria in order to answer a specific research 
question. It uses explicit, systematic methods that are selected with a view to minimizing bias, 
thus providing more reliable findings from which conclusions can be drawn and decisions 
made.‖ 22 
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CHAPTER 1:  BACKGROUND AND MOTIVATION FOR THE REVIEW 
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1.1. PLAIN LANGUAGE SUMMARY 
Statins are drugs of known efficacy in the treatment of high blood cholesterol and are 
recommended for the prevention of heart (cardiovascular) disease, the number one cause of 
death globally.    
 
Although statins are effective to decrease bad (LDL) cholesterol, the prevalence of their use is 
low. One explanation for this is improved access to health information from the Internet or 
other sources, increasing fears of the side effects of statins, which results in statin 
discontinuation. Concern has been expressed particularly about severe muscle toxicity as a 
side effect of statin use, which may initially present as a condition known as myopathy, a term 
used to refer to any muscle complaints. The symptoms of myopathy range from mild muscle 
aches, weakness and elevation of the muscle enzyme, creatine kinase (CK). Severe muscle 
toxicity, known as rhabdomyolysis, is diagnosed as very high CK levels and is often also 
accompanied by kidney failure.  
Symptoms of myopathy have been reported to prevent moderate exertion in daily activities, 
confine patients to bed and even result in cessation of employment, demonstrating a 
decrease in quality of life. Because high cholesterol doesn‘t have any symptoms, any 
unwanted side effect of a drug used for its management can undermine adherence to the 
drug, compromising treatment. This warrants research to better identify patients at risk for 
myopathy induced by statin use as well as to evaluate the current management strategies. 
The onset of myopathy may be aggravated by a higher statin dose, amongst other, but, to 
date, the exact cause of myopathy is unknown. One mechanism may be because statin use 
decreases blood levels of a nutrient called coenzyme Q10 (CoQ10), a powerful antioxidant 
that plays a role in muscle function. A decrease in blood and/or muscle levels of CoQ10 may 
thus contribute to the development of myopathy. Although the potential of the use of CoQ10, 
which is available as a non-prescription nutritional supplement, has been recognized, it has 
not been conclusively supported to form a part of medical guidelines to prevent or treat 
myopathy. In this review, only two small studies were identified that examined the effect of 
CoQ10 in statin-induced myopathy, one which is supportive of CoQ10 for statin-induced 
myopathy and the other not. Although CoQ10 may have numerous health benefits and is well 
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tolerated at high doses, its use continues to be considered only in certain patients until more 
clinical trials are conducted to conclude whether CoQ10 is effective and the cost of its use 
justified. 
1.2. INTRODUCTION 
Statins, also known as hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
are drugs of known efficacy in the treatment of hypercholesterolaemia and are recommended 
for both primary and secondary prevention of cardiovascular disease (CVD),26,27 which is the 
number one cause of death globally.28 With worldwide estimated sales grossing $19 billion 
annually, a figure that is consistently growing,29  statins are one of the top selling prescription 
drug families in the world.30  
Statins inhibit HMG-CoA reductase, an important enzyme for the synthesis of cholesterol, 
reducing low-density-lipoprotein (LDL) cholesterol by up to 60%, alongside many other 
beneficial effects.31 In some patients, statins may decrease CVD morbidity and mortality by 
25%.32 Six statins, namely lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin and 
cerivastatin, were initially approved by the United States Food and Drug Administration 
(FDA), and were introduced between 1987 and 1997.33 Although they fall under the same 
class and share a common mechanism of action, these statins differ in chemical structure, 
pharmacokinetic profile and efficacy in modifying blood lipids.34 Despite  overall efficacy for 
reducing LDL-cholesterol, the number of people receiving statins for their 
hypercholesterolaemia is very low, even among those who are aware of their condition.35 
Multinational data on the treatment of hypercholesterolaemia from the World Health 
Organisation (WHO) multinational monitoring of trends and determinants in cardiovascular 
disease cohort component, also known as the MONICA Project,35 reported that the 
prevalence of drug treatment was on average 8% in men and 6% in women. The study of 
Mitka (2003)30 also found that more than 40% of patients eligible for statin use were not 
receiving treatment. 
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1.2.1. Barriers to Statin Use 
One barrier to statin use has been affordability,30 which may explain the limited use. Another 
is improved access to information from sources such as the Internet, increasing patient fears 
of statin side effects. This may result in non-adherence to statin therapy as well as the use of 
alternative cholesterol-lowering therapies.32 Of the various adverse effects of statins, only 
liver‑ and muscle‑related toxicity are consistently reported.36 Liver toxicity is recognised as 
subclinical aminotransferase elevations and occurs in 1 to 2 % of patients. Clinically important 
liver injury is, however, uncommon.37 The American College of Cardiology (ACC), the 
American Heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI), 
define myopathy as a term that refers to any disease of the muscle, including toxic 
disorders.32 Current management guidelines implicate that the progressive worsening of the 
symptoms or markers of myopathy as an adverse effect warrants a reduction in the 
prescription dose of statins or temporary discontinuation of the drug,38  which compromises 
cardiovascular risk management.27 In the Prediction of Muscular Risk in Observational 
conditions (PRIMO) study,39 4% of patients developed symptoms of myopathy from statin 
therapy that confined them to bed or resulted in cessation of employment, and as many as 
38% had symptoms that prevented moderate exertion during daily activity. These are all 
factors affecting patient quality-of-life, a measurement that can be variable and that is mostly 
subjective in nature. Dimensions of patient quality-of-life include: the absence of distressing 
physical symptoms (e.g. pain and/or weakness and fatigue), emotional well-being, functional 
status (e.g. the ability to complete daily activities), quality of close interpersonal relationships, 
the ability to participate in and enjoy social interaction, satisfactory medical treatment and 
finances thereof, as well as intimacy, amongst other.40 Impairment of a patient‘s quality of life 
may explain the poor compliance to statins reported in the study of Jackevicius (2002) 41. In 
this study, 75% of the 85 020 patients using statins for the primary prevention of CVD had 
discontinued the drug, suggesting that they received no or limited benefit from its use. 
Overall, because hypercholesterolaemia is usually asymptomatic, any unwanted side effect, 
which may also affect quality of life, will undermine adherence to the drug used for its 
treatment.42 
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1.2.2. Coenzyme Q10 
 
Coenzyme Q10 (CoQ10), a fat-soluble nutrient, was first chemically synthesized in 1958, and 
was approved as a pharmaceutical drug in Japan for the treatment of congestive heart failure 
in 1974.43 In the USA, following the Dietary Supplement Health and Education Act (DSHEA), 
CoQ10 has been sold as a supplement to the diet since 1994.43 The efficacy of CoQ10 for the 
treatment of statin-induced myopathy is hypothesized due to the decreased plasma (and 
muscular) CoQ10 concentration observed after statin use, as well as the concomitant role of 
CoQ10 in muscle function.31 Although the use of CoQ10, which is available as a non-
prescription nutritional supplement, does not form part of current management guidelines for 
statin-induced myopathy, its potential has been recognized. To further this, the aim of the 
current study is to systematically review the available evidence regarding CoQ10 
supplementation for the treatment (elimination or improvement) of statin-induced myopathy. 
The outcomes could assist medical practitioners in determining whether CoQ10 
supplementation is indeed effective in improving/treating statin-induced myopathy and thus 
whether it should be a recommended treatment mechanism in clinical practice. 
1.3. DESCRIPTION OF THE CONDITION – STATIN-INDUCED MYOPATHY 
There are various definitions available for statin-induced myopathy. The ACC, AHA, NHLBI, 
FDA, and the National Lipid Association (NLA) have each proposed definitions for statin-
induced muscle effects (Table 1.1).38,44,45 
Myopathy has generally been defined as any muscle complaints or creatine kinase (CK) 
elevation with or without associated muscle symptoms.38 Biopsy evidence suggests that some 
statin-induced myopathic changes may be present in the context of normal CK levels - 
myopathy thus does not necessarily connote symptoms or any degree of CK elevation.47 In 
statin-treated patients, muscle-related symptoms range from mild, transient myalgia and 
myositis to rhabdomyolysis.48 These symptoms are typically reported in the proximal limbs 
and trunk.48-50 In general, patients with isolated and unilateral symptoms have an alternative 
explanation for their complaint.51 The specific clinical characteristics associated with the 
different classifications of symptomatic myopathy are summarized in Table 1.2. These are 
namely muscle aches and weakness, but may progress to renal dysfunction in 
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rhabdomyolysis. The terms myalgia, myositis and rhabdomyolysis are used to describe 
muscle toxicity – myopathy is the general term used to refer to all of these problems.  
1.3.1. Diagnosis 
It is important to differentiate between the clinical and laboratory characteristics that 
accompany each term. However, it appears that the definitions given by the Canadian 
Working Group, ACC, AHA and NHLBI differ to those given by the FDA in Table 1.1, where 
rhabdomyolysis is accompanied by definitive evidence of organ damage.  
Table 1.1: Proposed definitions for statin-induced myopathy 
Clinical entity ACC/AHA/NHLBI NLA FDA 
Myopathy General term referring 
to any disease of 
muscles 
Symptoms of myalgia 
(muscle pain or 
soreness), weakness, 
or cramps, plus CK 
>10 x ULN 
CK > 10 x ULN 
Myalgia Muscle ache or 
weakness without CK 
elevation 
NA NA 
Myositis Muscle symptoms 
with CK elevation 
NA NA 
Rhabdomyolysis Muscle symptoms 
with significant CK 
elevation (typically 
>10 x ULN), and 
CK (usually with 
brown urine and 
urinary myoglobin) 
CK >10 000 IU/L or 
CK >10 x ULN plus 
an elevation in 
serum creatinine or 
medical intervention 
with intravenous 
hydration 
CK >50 x ULN and 
evidence of organ 
damage, such as 
renal compromise 
ACC/AHA/NHLBI = American College of Cardiology/American Heart Association/National 
Heart, Lung, and Blood Institute; FDA = U.S. Food and Drug Administration; NA = not 
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available; NLA = National Lipid Association; ULN = upper limit of normal; CK =Creatine 
Kinase 
Source: Mancini et al (2011)46 
According to the definitions by the ACC, AHA and NHLBI, diagnosis can generally be eased 
by means of measurement of the patients‘ plasma CK. According to the Canadian Working 
Group, however, hyperCKaemia may not necessarily confirm diagnosis. Given the above 
differences, it comes by no surprise that, in the study of Thompson (2006) 52, the Muscle 
Expert Panel recommended that the given definitions of statin-induced myopathy be 
standardized. They found it difficult to diagnose muscle problems in clinical practice and to 
compare the results of different studies with the varying definitions presented. 
1.3.2. Symptoms 
Rhabdomyolysis is the main life-threatening adverse effect of statin-induced myopathy due to 
the risk of acute renal failure. However, it continues to be a rare condition, affecting around 
0.01 percent of statin users.27 For all statins (excluding cerivastatin), the incidence of 
rhabdomyolysis (using the FDA definition) in two cohort studies was 3.4 (1.6 to 6.5) per 100 
000 person-years.53 Cerivastatin was withdrawn from the US market in August 2003 54 
because of an apparent 15- to 80-fold increased risk of rhabdomyolysis.55 A meta-analysis 
from 74 102 patients in 35 randomised clinical trials through December 2005 compared statin 
monotherapy versus placebo, with a follow-up period from 1 to 65 months. When patients 
treated with cerivastatin were excluded, there was no significant risk of myalgias, CK 
elevation, rhabdomyolysis, or discontinuation of the statin due to any adverse effect.56 There 
was a risk difference of 4.2 [95% confidence interval (CI), 1.5– 6.9; P <0.01] for statin-induced 
increases in transaminases per 1000 patients. A meta-analysis of 83 858 patients treated with 
atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, and only 114 with cerivastatin 
also revealed a low incidence of myositis (0.11%) and rhabdomyolysis (0.016%), with no 
significant increase in the patients using statins compared with the patients using the 
placebo.57 In general, rhabdomyolysis is more common with higher statin doses (ranging from 
40 mg to 80 mg daily, depending on the type of statin)36,39,53 and when fibrate therapy is 
administered simultaneously.58 
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Muscle weakness, tiredness, cramps and/or increased CK activity remain the most frequently 
reported adverse effects of statin therapy, affecting from 0.5 to 2 31 and up to 10-15 59 percent 
of statin users. Among 68 629 participants in 12 clinical trials, muscle pain, tenderness or 
weakness sufficient to consult a physician or to stop taking treatment occurred in 97 
participants using statins and 92 participants using a placebo per 100 000 person-years of 
treatment.53 In the Heart Protection Study, the largest trial examining statin-induced 
myopathy,60 10 269 patients received 40 mg of simvastatin and 10 267 a placebo for a 
median of 5 years. At least one episode of unexplained muscle pain or weakness occurred in 
32.9% of the simvastatin and 33.2% of the placebo group, but only 0.5% in each group 
stopped treatment because of these complaints. 
The prevalence of muscle complaints has thus been very similar in statin and placebo groups 
of controlled trials. However, the PRIMO study did report muscular complaints in 10.5% of 
7924 unselected patients treated with high-dosage statin therapy (fluvastatin 80 mg, 
atorvastatin 40 to 80 mg, pravastatin 40 mg, or simvastatin 40 to 80 mg) for at least 3 
months.39 Subjects of this report were, however, not blinded and data were obtained by 
questionnaire. The results may also more closely represent the experiences of physicians 
prescribing higher statin doses.61 Given the inconsistent definitions, however, it is difficult to 
compare the incidence of statin-induced myopathy in research with the incidence in clinical 
practice. Post-marketing surveillance through the US FDA Adverse Event Reporting System 
(AERS) has also documented low reporting rates of statin-induced myopathy,32 meaning that 
incidence may indeed be much higher than those documented. 
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Table 1.2: Integrated Canadian Working Group consensus terminology for myopathic 
syndromes and hyperCKaemia* 
Terms Laboratory characteristics  Clinical characteristics 
Myopathy NA General term referring to any 
disease of the muscle 
Symptomatic myopathy   
Myalgia CK<ULN Muscle ache/weakness 
Myositis CK>ULN Muscle ache/weakness 
Rhabdomyolysis CK> 10x ULN (CK>10 000 
U/L) 
Muscle ache/weakness; 
renal dysfunction may result 
from myoglobinuria; need for 
hydration therapy 
HyperCKaemia   
Mild, grade 1 CK>ULN; <5x ULN May/may not have myositis 
Mild, grade 2 CK>5x ULN; <10x ULN May/may not have myositis 
Moderate CK>10x ULN; <50x ULN May/may not have 
rhabdomyolysis with/without 
renal dysfunction 
Severe CK>50x ULN May/may not have 
rhabdomyolysis with/without 
renal dysfunction 
CK=creatine kinase; NA=not applicable; ULN=upper limit of normal 
Source: Mancini et al (2011)46 
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1.3.3. Measurement  
To date, a standardized measurement tool that is specific to myopathy does not exist. Studies 
that have measured myopathy have merely listed the prevalence of symptoms; namely 
muscle weakness, tiredness, cramps and/or increased CK activity; or have adopted tools that 
are used to assess pain. Pain is, however, difficult to measure as it is a subjective sensation. 
Several features or attributes may describe pain – these include the quality, location, 
intensity, emotional impact and frequency, amongst others. Pain intensity is, however, one of 
the most relevant attributes.62 One of the tools to assess a patient‘s pain experiences is called 
the Brief Pain Inventory (BPI), which is considered a multidimensional pain measurement tool. 
It provides information about the history, intensity, location, and the quality of the patient‘s 
pain. Numeric scales from 0 to 10 are used to indicate the intensity of pain overall, at its 
worst, at its least, and at the present time; a percentage scale indicates pain relief from the 
relevant therapies; and a figure resembling the human body is given to the patient to shade 
the area which best positions where his/her pain is being experienced. Finally, seven 
questions determine the patients‘ pain interference with daily functioning. This tool has been 
validated in patients suffering from pain in a variety of conditions as well as from different 
geographical areas.63,64 Another tool used is called the Visual Analogue Scale (VAS), which is 
considered a one-dimensional pain measurement tool. It mostly uses a simple numeric scale 
of 0 to10 or a horizontal 100-mm visual analogue scale and is often considered the ideal tool 
because it is continuous, is similar to a ratio scale, and is more independent from language 
than a verbal scale.65,66 However, the validity of this scale is strongly dependent on the 
method of administration as well as the instructions given to the participants of the study.65 
Although the BPI and VAS are well researched and their use recommended by the Expert 
Working Group of the European Association of Palliative Care, amongst other, most of the 
evidence is in cancer patients and/or palliative care. One should also note that symptoms of 
myopathy range from mild, transient muscle aches to muscle aches with weakness in statin-
treated patients – myopathy thus does not always necessarily connote pain.48 In the study of 
Thompson (2006) 52, the Muscle Expert Panel implicated that the evaluation of statin-induced 
myopathy should include the evaluation of the minor symptoms of myopathy listed above, 
even when they occur without CK elevation. These minor symptoms may still affect the 
patient‘s quality of life as well as adherence to statin therapy, and thus CVD management.52 
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Two of the recommendations to researchers, funding agencies and pharmaceutical 
companies in the study of Thompson (2006)52 were to 1) develop a tool to measure mild 
statin-induced myopathy and 2) to incorporate measurements of muscle strength into 
research on statin therapy, which would include handgrip, elbow flexor and knee extensor or 
strength.52 These recommendations have not yet been implemented. 
 
1.3.4. Risk Factors  
 
Two proposed categorisations for the risk factors to statin-induced myopathy have been 
identified. One is from the study of Venero (2009) 61, where risk factors were categorized as 
conditions that increase statin serum and muscle concentration, drugs that affect statin 
metabolism, and factors that increase muscle susceptibility to injury (Table 1.3). The other 
categorisation is from the ACC/AHA/NHLBI clinical advisory board, who propose that risk 
factors be categorized into patient- and treatment-related factors (Table 1.4).  With regards to 
the dose of statin: simvastatin, pravastatin and rosuvastatin at doses double those currently 
marketed have caused higher rates of muscle damage. In patients post-myocardial infarction, 
simvastatin at 80 mg/day resulted in more frequent marked increases in CK levels versus 
simvastatin at 40 mg/day.67 The type of statin, as well as the extent of lipid reduction are also 
proposed factors that may increase risk to statin-induced myopathy. Muscle toxicity has been 
reported with all available statins.57 From 2002 to 2004 however, the FDA AERS rates for 
myopathy were the lowest for fluvastatin (0.43 cases per 1 million prescriptions) and the 
highest for rosuvastatin (2.23 cases).32  
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Table 1.3: Risk factors associated with statin-induced myopathy 
1. Factors related to an increase in statin serum level 
a. Statin dose 
b. Small body frame 
c. Decreased statin metabolism and excretion 
i. Drug–drug interactions 
ii. Grapefruit juice (possibly also pomegranate & star fruit) 
iii. Hypothyroidism and diabetes mellitus  
iv. Advanced age 
v. Liver disease 
vi. Renal disease 
2. Factors related to muscle predisposition 
a. Alcohol consumption 
b. Drug abuse (cocaine, amphetamines, heroin) 
c. Heavy exercise 
d. Baseline muscular disease 
i. Multisystemic diseases: diabetes mellitus, hypothyroidism 
ii. Inflammatory or inherited metabolic muscle defects 
Source: Venero (2009)61 
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Table 1.4: ACC/AHA/NHLBI risk factors to statin myopathy 
 1.Patient-related factors 
a.Advanced age 
b.Female gender 
c.Small body size 
d.Multisystem disease (esp. liver and/or 
kidney) 
e.Alcoholism 
f.Excessive grapefruit consumption 
g.Excessive physical activity 
h.Family history of myopathy while receiving 
lipid-lowering therapy 
i.History of myopathy while receiving another 
lipid-lowering therapy 
j.History of CK elevation 
k.Hypothyroidism 
l.Major surgery or the preoperative period 
2.Treatment-related factors 
a.High-dose statin therapy 
b.Interactions with concomitant drugs 
i.Fibrates 
ii.Cyclosporine 
iii.Antifungals 
iv.Macrolide antibiotics 
v.Nefazodone 
vi.Amiodarone 
vii.Verapamil 
viii.Protease inhibitors (anti-HIV drugs) 
Source: Joy (2009)32 
In a double-blind, randomised, cross-over study, subjects who tested positive for myalgia 
showed greater decreases in total and LDL-cholesterol when compared to subjects who did 
not develop myalgia,68 suggesting that muscle toxicity may be an effect of lipid reduction.52 
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1.3.5. Current Recommendations 
 
Statins are prescribed for chronic use (for a duration of 3 months or longer) and are usually 
continued unless liver enzymes increase to more than three times the upper limit of normal – 
liver and muscle enzymes may be checked upon the initiation of therapy, and at least one set 
of liver enzymes will be tested between one to three months later, and annually thereafter.39 
Muscle enzymes need not be checked regularly unless the patient develops muscle 
symptoms and, if damage is suspected, statin use is usually stopped and CK measured.31 
The study of Mancini et al (2011) 46, however, reported that the public consciousness about 
adverse effects and the commonness of symptoms such as myalgia suggests that it is 
prudent to measure CK at 6 to 12 weeks, usually at the time of a repeat lipid assessment. 
Although there are currently no definitive treatment mechanisms for statin-induced myopathy, 
there are several options that can be explored and implemented according to practicality from 
patient to patient. These options include the use of different statins or a lower statin dose, as 
well as nutrients such as vitamin D and E. In general, symptoms that are not minor/not 
tolerated motivates for the statin to be stopped until the patient is asymptomatic.46 The same 
statin at the same dose may then be restarted. If the symptoms reoccur, it is suggestive of 
statin intolerance, at which stage a lower dose of statin and/or a different type of statin can be 
considered. Only when a well-tolerated statin does not achieve adequate lipid-lowering, the 
statin can be replaced or supplemented with adjunctive use of non-statin lipid-lowering 
therapies such as Ezetimibe, Niacin, Fibrates or Bile Acid Sequestrants, amongst other.46 
However, no controlled trials exist to implicate the use of Vitamin D to relieve statin-induced 
myopathy and a severe Vitamin D deficiency is associated with intrinsic muscle disease, 
which is not related to statin use. In one study of 38 vitamin D-deficient patients, Vitamin D 
was given at 50 000 IU per week for 12 weeks, where after myalgia was resolved in 92% of 
the patients.69 Vitamin E was also shown to have no value for pain relief in one controlled 
trial.70 
 
1.4. DESCRIPTION OF THE INTERVENTION – COENZYME Q10 
CoQ10, also known as ubiquinone (Figure 1.1), is a natural component of living cells. CoQ 
belongs to a homologous series of compounds that share a common benzoquinone ring 
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structure, but differ in the length of the isoprenoid side chain. In humans and a few other 
mammals, this side chain contains 10 isoprene units, and is thus called CoQ10.71 
1.4.1. Measurement  
Plasma/serum CoQ10 concentrations are used to assess CoQ10 status in humans, primarily 
because sample collection is much easier using these methods.71 Plasma CoQ10 
concentration may not be a good indicator of CoQ10 concentration in the tissue,72,73 but it 
serves as a good measure of the overall CoQ10 status in the individual and also as a guide to 
the dose of CoQ10 the patient may require.71 Several methods for this measurement are 
preferred,71 and have been tested in studies from the year 1987.74 These methods include 
mostly ultraviolet and electrochemical detection and/or liquid chromatography.75-80 Thus far, a 
single reference value/range for plasma CoQ10 has not been specified. A few studies have 
indicated normal plasma levels for males and females, (Table 1.5) which appear to be in the 
range of 0.227 to 1.9 mmol/l.  
1.4.2. Functions  
CoQ10 has many functions: it is a powerful antioxidant,33 membrane stabilizer,33 and may 
have an effect on gene expression.84 The major physiological role of CoQ10 is that it 
functions as an irreplaceable component of the mitochondrial energy electron transduction 
chain and adenosine triphosphate (ATP) production.85 These high-energy phosphates are 
necessary for many cellular functions, including muscle contractions.86 Statins block the 
conversion of HMG-CoA to mevalonate by inhibiting HMG-CoA reductase, decreasing 
cholesterol production but also suppressing formation of isoprenoids (Figure 1.3).57 It is well 
documented that serum CoQ10 levels decrease with statin treatment (Table 1.6).87 Statins 
are known to reduce CoQ10 levels in the plasma, where supplementation with CoQ10 will 
increase these levels without affecting the efficacy of the statin therapy.31,88-108 The highest 
decreases in CoQ10 in these studies appear to be related to a higher dose of statin as well as 
longer duration of statin use.88,94,95  Because plasma and intramuscular CoQ10 levels do not 
correlate, different regulatory mechanisms have been suggested.109 However, the effect of 
statins on intramuscular CoQ10 may also be drug and dose-dependent. Very few studies 
have investigated skeletal muscle CoQ10 levels after statin therapy. However, data from 
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these representative human studies show that low dose statin treatment (<40 mg daily) does 
not significantly reduce intramuscular CoQ10,32,94,95 even when used for longer durations of 
up to 6 months. Hence its function in the electron transport chain, a CoQ10 deficiency 
resulting from statin therapy may impair muscle energy metabolism and therefore may 
contribute to the development of statin-induced myopathy.87 
 Table 1.5: Serum/plasma CoQ10 reference values 
Serum/plasma CoQ10 
(mmol/l) - Females 
Serum/plasma CoQ10 
(mmol/l)- Males 
Reference 
0.43 to 1.47 0.40 to 1.72 
Kaikkonen (2002)81 
 
0.50–1.9 
 
Miles et al (2003)82 
 
0.227 to 1.432 (mean of 0.675) 
 
Duncan (2005)83 
 
 
The plasma depletion of CoQ10 due to statin use in humans was also associated with an 
elevation in lactate to pyruvate ratio in the study of De Pinieux et al (1996) 97, suggesting a 
shift toward anaerobic metabolism and possible impairment in mitochondrial bioenergetics. 
This may also contribute to muscle injury and myopathy during statin use due to the 
importance of the mitochondria in muscle function. 
CoQ10 is a fat-soluble nutrient (a quinone) but not considered a vitamin as it is synthesized in 
in all cells in healthy human subjects from tyrosine (or phenylalanine) and mevalonate (Figure 
1.1).71 Because CoQ10 is lipophilic, its absorption follows the same process as that of lipids in 
the gastrointestinal (GI) tract.71 It is transported to the small intestine where secretions from 
Stellenbosch University http://scholar.sun.ac.za
  - 17 - 
the pancreas and bile facilitate emulsification and micelle formation. Thereafter it passes into 
the lymphatic system and finally to the blood and tissues. Almost all of the CoQ10 in the 
human circulation exists in its reduced form, ubiquinol (Figure 1.2).82,111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formation of mevalonate is the rate limiting step in synthesis.57 
Figure 1.1: Endogenous synthesis of ubiquinone and cholesterol 
Source: Palomaki (1998)110  
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1.4.3. Digestion 
After absorption, ubiquinol initially forms a part of lipoproteins. These particles are converted 
to chylomicron remnants in the circulation by lipoprotein lipase and are then taken up rapidly 
by the liver. Here CoQ10 forms a part of very-low-density-lipoprotein (VLDL) and/or LDL 
particles, which are rereleased into the circulation.112 High-density-lipoprotein (HDL) particles 
also contain a small amount of CoQ10. 
 
 
 
 
 
 
 
About 95% of CoQ10 in human circulation exists in its reduced form, Ubiquinol. 
Figure 1.2: Molecular structures of ubiquinone (A) and ubiquinol (B) 
Source: Mabuchi et al (2005)107 
CoQ10 is mainly found in active organs, such as the heart, kidney and liver.114 Only up to 
10% of total CoQ10 is located in cytosol and about 50% in mitochondria, making it vulnerable 
to free radicals that may form during oxidative phosphorylation.115 The total amount of CoQ10 
in an adult human body must be replaced daily by endogenous synthesis and dietary 
intake.116 It is thought that 50% of CoQ10 is obtained through exogenous sources and the 
other 50% through endogenous synthesis,117 with an average turnover rate in the body being 
around 4 days.118 Exogenous sources of CoQ10 need to be increased if endogenous 
synthesis is impaired. Low levels of CoQ10 are typically found in disease or ageing.119-122 
Table 1.6 presents genetic mutation, aging, cancer and statin type drugs as causes for a 
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serum or tissue decrease in CoQ10 and the relative tissue analyses to determine whether 
there is a deficiency.42 
1.4.4. Sources  
Exogenous sources of CoQ10 include various food items and nutritional supplements. The 
content in food is, however, generally low - the average dietary intake is between 3 and 6 mg 
daily.125 Although studies regarding the CoQ10 content of different foods are limited, it 
appears that meat and fish have the highest contents due to their relatively high levels of fat 
and mitochondria.126 An overview of CoQ10 contents in some common foods can be seen in 
Table 1.7. A more comprehensive list can be sourced from the study of Pravst (2010) 127. 
CoQ10 as a dietary supplement, however, has been extensively researched in healthy 
subjects and patients (mostly chronic heart failure) and results in a definitive increase in 
plasma CoQ10 concentrations after routine supplementation of 2 weeks or longer.71 A 1.470 
130 to 4.074 131 fold increase in CoQ10 concentration from baseline to after the intervention 
was seen in studies with chronic low/moderate doses (30 to 300 mg) of CoQ10. Up to 7.5 fold 
increases were seen with chronic high (300 to 3000 mg) doses.132 It is currently available in 
different supplemental preparations, including crystalline CoQ10 powder in hard gelatin 
capsules, oily dispersions and as solubilizates in soft-gel capsules,133 all which can be bought 
over the counter. The efficacy of absorption of orally administered preparations may, 
however, be poor because they are mostly lipophilic and have a relatively large molecular 
weight.71,134 Studies also cite slow absorption of CoQ10 from the GI tract (Tmax = 
>6hours).135,136 The extent of the increase in the serum level of CoQ10 will depend on factors 
such as the dosage, duration and also the type of formulation. Large single doses of CoQ10 
either as a powder or as an oil-suspension has little or no effect in human subjects,81,137,138 
whereas, after two weeks of supplementation, concentrations of plasma CoQ10 was seen to 
stabilize in the study of Tomono (1986)136 and more recently in the study of Hosoe (2007)139. 
In this study, CoQ10 concentrations were above reference values in the study participants 
and increased according to the CoQ10 dose given. The increases were, however, not linear. 
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Table 1.6: CoQ10 deficiency in humans 
Basis Tissue analysis Decrease from 
control (%) 
Reference 
Genetic Lymphocytes - Rotig et al (2000)123 
Genetic Skin fibroblasts 90 Rotig et al (2000)123 
Age*** Myocardium 72 Rosenfeldt et al (1999)120 
Age* Heart 58 Kalen (1989)116 
Age Pancreas 83 Kalen (1989)116 
Age Adrenal 50 Kalen (1989)116 
Age Liver 17 Kalen (1989)116 
Age Kidney 45 Kalen (1989)116 
Age Skin epidermis 75 Hoppe et al (1999)119 
Pravastatin0 Serum 20 Mortensen et al (1997)94 
Lovastatin0 Serum 29 Mortensen et al (1997)94 
Simvastatin0 Serum 26 Bargossi et al (1994)89 
Cancer (pancreas) Serum 30 Folkers et al (1997)124 
* Change from age 19–21 to age 77–81. 
** Change from age 30 to age 80. 
*** Change from avg. age 58 +1.7 to 76 + 6.8. 
0HMG CoA reductase inhibitors of isoprene synthesis. 
Source: Crane (2001)42 
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Better absorption is mostly achieved with oil-based forms of CoQ10 as a soft-gel 
capsule.125,140 Absorption may also be enhanced if the nutritional supplement of CoQ10 is 
ingested in the presence of fat due to its lipophilic nature, which is the rationale for oil-based 
preparations. The importance of CoQ10 formulation for bioavailability has been suggested by 
the continuous search for formulations with increased absorption.71,142,143 Table 1.8, adapted 
from Bhagavan (2006)71, presents data on the dose, duration and net plasma increase in 
CoQ10 concentration from representative human studies. Plasma CoQ10 increases range 
from 0.5 µmol/L (300 mg CoQ10 emulsion) to 3.255 µmol/L (120 mg solubilized CoQ10). 
Despite the higher CoQ10 dose, the limited bioavailability of the formulation appears to result 
in smaller changes in the CoQ10 plasma value. Bhagavan (2006)71 reported that individual 
variability in plasma response to ingested CoQ10 was observed in the studies in Table 1.8 as 
was indicated by large standard deviations.71 
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Table 1.7: An overview of the CoQ10 content in some commonly eaten foods 
 Food CoQ10 µg/g Daily portion 
g/day 
CoQ10 intake 
mg/day 
Meat Pork heart 203 120 24 
 Chicken leg 17 120 2 
 Beef heart 41 120 4.8 
 Beef liver 19 120 2.3 
 Lamb leg 2.9 120 3.5 
Fish Herring 27 26 0.7 
 Trout 11 100 1.1 
Vegetable Cauliflower 0.6 200 0.12 
 Spinach 2.3 200 0.46 
Fruit Orange 2.2 200 0.44 
Starch Potato 0.24 200 0.05 
Source: Crane (2001)42 
Data from: Lester (1959)128 and Weber (1997)129 
More studies are needed to determine whether patient age, gender, lipoprotein status and 
diet, amongst other factors, may affect the bioavailability of CoQ10 with chronic dosing.145 
1.4.5. Recommendations for Intake 
The suggested daily intake of CoQ10 from exogenous sources varies from 30 to 100 mg for 
healthy subjects and 60 to 1200 mg when used in combination with other therapies in some 
medical conditions.146-148 The acceptable daily intake (ADI) is 12 mg/kg/day, calculated from 
the no-observed-adverse-effect level (NOAEL) of 1200 mg/kg/day derived from a 52 week 
Stellenbosch University http://scholar.sun.ac.za
  - 23 - 
chronic toxicity study in rats.149,150 CoQ9 is, however, the major CoQ homologue in rats, so 
they may not be the appropriate animal model for studying CoQ10 intake and metabolism.71 
Table 1.8: Data from representative human studies on the dose, duration and net plasma 
increase in CoQ10 concentration of different formulations 
CoQ10 
Formulation 
Daily Dose 
(mg)  
Duration of 
intervention 
with CoQ10 
Plasma CoQ10 
increase 
(micromol/l) 
Reference 
Oil based 90 9 months 1.214* Folkers (1994)143 
Oil based 90 2 weeks 1.200a Weber (1994)135 
Oil based 100 2 weeks 0.524b Lonnrot et al (1996)144 
Powder based 90 2 months 1.810 Kaikkonen et al (1997)138 
Oil based 90 2 months 1.900 Kaikkonen et al (1997)138 
Powder based 120 3 weeks 1.310 Chopra (1998)133 
Oil based 120 3 weeks 1.008 Chopra (1998)133 
Solubilized 120 3 weeks 3.255 Chopra (1998)133 
Oil based 300 1 week 0.530 Lyon (2001)140 
Emulsion 300 1 week 0.500 Lyon (2001)140 
Plasma CoQ10 values corrected for baseline. 
*Whole blood; CoQ10 in divided doses,aExtrapolated from figure,bWith 500 mg Vitamin C. 
Source: Bhagavan (2006)71 
Thus far, no adverse effect directly related to CoQ10 consumption by humans exists, 
meaning that there is no reference NOAEL and that an upper limit (UL) cannot be derived.151 
The dosages of CoQ10 used in clinical trials are thus evaluated according to the presence of 
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adverse effect/s at the level of CoQ10 supplemented – this is also known as the observed 
safety level (OSL).151 Risk assessment for CoQ10 based on various clinical trial data indicate 
that the OSL for CoQ10 is 1200 mg/day/person,149 In the study of Shults et al (2002) 152, up to 
1200 mg CoQ10 per day was given to patients with Parkinson‘s disease for 16 months, and in 
the Huntington Study Group (2001) 153, 600 mg CoQ10 per day was given to patients with 
Huntington‘s disease for 30 months. In these studies, the frequency of side effects were 
almost equal to that in the relative control groups, which indicated that the doses of CoQ10 
given were within tolerable limits. It is notable, however, that the studies mentioned are on 
patients and not healthy individuals. No safety data of CoQ10 in healthy individuals have 
been reported, however typical doses of CoQ10 supplementation in most conditions is 60 to 
200 mg daily in divided doses.107 Up to 15 mg/kg/day are being given for mitochondrial 
cytopathy.154 More recent data document the safety and tolerability of CoQ10 at doses as 
high as 3000 mg a day in patients with Parkinson‘s disease and amyotrophic lateral 
sclerosis.132,155 
1.4.6. Benefits of Supplementation 
There are numerous health benefits with CoQ10 supplementation. A large number of these 
studies demonstrating benefits relate to CVD where CoQ10 has been used in combination 
with standard medical therapy.156 Cardiovascular benefits of CoQ10 may be due to its 
bioenergetic role, its capability of antagonizing oxidation of plasma LDL, and its ability to 
improve endothelial function.157 Thus far, cardiovascular benefits reported include improved 
endothelium-bound extracellular superoxide dismutase (ecSOD)158 in patients affected by 
coronary artery disease; decreases of up to 17 mmHg in systolic and 10 mmHg in diastolic 
blood pressures;159 and improved diastolic dysfunction in hypertrophic cardiomyopathy. Some 
other claims for the use of CoQ10 includes an anticancer effect through immune stimulation, 
decreased insulin requirements in patients with diabetes,160-164 slowed progression of 
Parkinson's disease, improved semen quality in men with idiopathic infertility,165 reduced  risk 
of pre-eclampsia and protection against anthracycline cardiotoxicity.107,166 Although studies 
suggest that CoQ10 may be useful in treating these disorders, amongst others (e.g. Multiple 
Sclerosis and Huntington‘s disease), results are unclear mostly due to the design of the 
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available trials and thus the quality of the evidence - more trials are needed for conclusive 
results.  
1.4.7. Adverse Effects of Supplementation 
Overall, CoQ10 is deemed safe as a dietary supplement. High doses of oral CoQ10 given 
over longer periods of time is well documented in humans,167 but GI symptoms such as loss 
of appetite, abdominal pain, nausea and vomiting; and central nervous system changes such 
as dizziness, photophobia, irritability and headaches may occur.168 Other adverse effects 
include itching, rash, fatigue and flu-like symptoms.168 Symptoms were found in 24 cases in a 
randomised, controlled trial (RCT)169 and were said to be caused by the oil content of the 
CoQ10 test capsules. Since commercial capsules use oil as a base due to the lipophilic 
nature of CoQ10, GI symptoms should be monitored, especially when high doses are taken 
over a short period of time.169 
 
Currently there are no known contra-indications for CoQ10 supplementation other than being 
undertaken with the chemotherapeutic agent, adriamycin, as CoQ10 affects it‘s 
metabolism.170 CoQ10 may also decrease a patient‘s response to Warfarin.168 
 
1.5. HOW THE INTERVENTION MIGHT WORK 
The exact pathophysiology of statin-induced myopathy is unknown. There are many possible 
mechanisms, one which is believed to be because statins inhibit mevalonate production, 
which results in a decrease in the formation of products of the mevalonate pathway (Figure 
1.3) – one of these products is CoQ10.31 A CoQ10 deficiency has merely been hypothesized 
to be a cause of statin-induced myopathy as CoQ10 is involved in mitochondrial electron 
transfer and serves as an important intermediary in the oxidative phosphorylation pathway.171 
Not many intervention studies on the efficacy of CoQ10 in statin-induced myopathy exist to 
confirm the etiological role of CoQ10 in statin-induced myopathy. In the study of Caso (2007) 
70, oral CoQ10 was given to patients at 100 mg per day for 30 days to evaluate the effect on 
symptoms of myopathy. The Pain Severity Score (PSS) and pain interference with daily 
activities (PIS) for the CoQ10 group decreased significantly. Sixteen of the 18 participants 
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receiving CoQ10 reported pain relief, which included a decrease in pain, ache, burning 
sensation and overall muscle fatigue. These findings suggested that CoQ10 may be 
beneficial for patients using statins by decreasing myopathic symptoms and improving 
subject‘s quality of life. However, in the study of Young et al (2007) 27, where oral CoQ10 was 
given to patients at 200 mg per day for 12 weeks to also evaluate the effect on symptoms of 
myopathy, there was no difference in the change in pain scales between the CoQ10 and the 
control group. No significant beneficial effect of oral CoQ10 supplementation on simvastatin 
tolerability and myalgic symptoms in patients could thus be demonstrated. Although both of 
these studies were comparative, they included only a small number of participants given the 
statistics of CVD. A conclusion cannot be drawn from the data as one study was positive and 
the other not, the efficacy of CoQ10 is thus inconclusive. The study of Langsjoen (2005)172 is 
a prospective analysis in which cardiology clinic patients on statin therapy were evaluated for 
possible adverse effects, including myalgia and fatigue, amongst other. All patients 
discontinued statin therapy due to side effects and began supplemental CoQ10 at an average 
of 240 mg/day upon the initial visit. The prevalence of patient symptoms on initial visit and on 
most recent follow-up demonstrated a decrease in fatigue and myalgia, and it was concluded 
that statin-related side effects were reversible with the combination of statin discontinuation 
and supplemental CoQ10. Although positive, the study was not a RCT and statin therapy was 
discontinued when CoQ10 supplementation commenced, which is seen as two simultaneous 
interventions. 
1.6. MOTIVATION FOR THE REVIEW 
Statins are drugs of known efficacy in the treatment of hypercholesterolaemia. However, 
statin-induced myopathy, an adverse effect of statins in up to 15% of its users, has warranted 
a reduction in the prescription dose or temporary discontinuation of the drug. Statin-induced 
side effects are far more common than previously published,172,173 so statin-induced myopathy 
will probably increase, especially with greater numbers of people starting high-dose statin 
therapy. This warrants research to better identify patients at risk for statin-induced myopathy 
as well as to evaluate the current management strategies.32,172 The exact mechanism of 
statin-induced myopathy remains unknown, but the potential of CoQ10, available as a non-
Stellenbosch University http://scholar.sun.ac.za
  - 27 - 
prescription nutritional supplement, has been recognized due to decreased human CoQ10 
levels found after statin use, and the concomitant role of CoQ10 in muscle function. 
 
Healthcare providers have immense amounts of information, including healthcare research, to 
process. They thus have limited time and/or resources to search for information, interpret it, 
as well as incorporate it into healthcare decisions. The purpose of this systematic review is 
thus to identify, appraise and synthesize the research-based evidence on CoQ10 for statin-
induced myopathy for this purpose.22 A meta-analysis was planned to provide more precise 
estimates of the effect of CoQ10 for statin-induced myopathy than what can be determined in 
individual studies. It may also facilitate investigation of the consistency of evidence across the 
studies found as well as explore the differences across these studies.22 A previous systematic 
review on the role of CoQ10 in statin-induced myopathy was completed in 2007. In this review 
by Marcoff (2007) 173, the search for English-language studies, completed in August 2006, 
used PubMed as the only database and a meta-analysis was not attempted as only the 
abstracts of relevant studies could be obtained. The review concluded that there was not 
enough evidence to confirm the etiological role of CoQ10 in statin-induced myopathy and that 
large, well-designed, clinical trials were required to address the issue.173 The current review 
aimed to improve on the methodology adopted in the study of Marcoff (2007)173 by completing 
a more comprehensive search of available databases. Searching merely one database may 
not have been sufficient to identify all relevant studies for inclusion in the review. The 
identification of more RCTs may also allow for meta-analyses of results. 
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CHAPTER 2:  METHODOLOGY 
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2.1. RESEARCH QUESTION 
In adults with symptoms of statin-induced myopathy, does CoQ10 supplementation act as an 
effective treatment by improving symptoms compared to a placebo/similar antioxidant/no 
intervention? 
2.2. OBJECTIVES 
2.2.1. Primary Objectives 
The primary objectives of the review were as follow: 
2.2.1.1. To determine the effect of CoQ10 supplementation on the severity of statin-induced 
myopathic symptoms as compared to controls (placebo/similar antioxidant/no 
intervention). 
2.2.1.2. To determine the effect of CoQ10 supplementation on plasma CK levels compared to 
a placebo/similar antioxidant/no intervention. 
2.2.1.3. To determine the effect of CoQ10 supplementation on intramuscular and plasma 
CoQ10 levels compared a placebo/similar antioxidant/no intervention. 
2.2.1.4. To determine whether any adverse effects of CoQ10 supplementation; such as 
abdominal pain, nausea and vomiting or headaches; are experienced as compared to 
a placebo/similar antioxidant/no intervention. 
2.2.2. Secondary Objectives 
The secondary objectives of the review were as follow: 
2.2.2.1. To determine the average duration of CoQ10 supplementation to elicit a positive 
response. 
2.2.2.2. To determine the average dose of CoQ10 supplementation required to elicit a positive 
response. 
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(A positive response is defined as a decrease in myopathic pain intensity/frequency, plasma 
CK levels and symptoms from the adverse effects of CoQ10, if any.) 
2.3. CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW   
2.3.1. Types of Studies   
Randomised controlled trials (RCTs). 
2.3.2. Types of Participants   
Adults (mean of 18-64.99 years) of all race/ethnic groups and gender on statin therapy with 
reported myopathic symptoms from no other known cause. Elderly patients were excluded as 
their CoQ10 levels are depleted at baseline irrespective of disease status (see Table 1.6). 
2.3.3. Types of Interventions   
2.3.3.1. Intervention 
Pure oral supplement of CoQ10 irrespective of dose, duration and frequency. 
2.3.3.2. Control 
Placebo, a similar antioxidant, or no intervention. 
2.4. TYPES OF OUTCOME MEASURES 
2.4.1. Primary Outcomes   
 The severity of myopathic symptoms 
2.4.2. Secondary Outcomes   
 Plasma creatine kinase (CK) (U/L) 
 Intramuscular CoQ10 (µmol/kg) 
 Plasma CoQ10 (µmol/L)  
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 Adverse effects of CoQ10 such as gastrointestinal symptoms (loss of appetite, abdominal 
pain, nausea and vomiting) and central nervous system changes (dizziness, photophobia, 
irritability and headaches). Other adverse effects include itching, rash, fatigue and flu-like 
symptoms. 
2.5. SEARCH METHODS FOR IDENTIFICATION OF STUDIES   
2.5.1. Electronic Searches 
An electronic search for studies was performed by the principle investigator (LP) with the 
assistance of a qualified librarian (WP) in March 2011 and again in November 2011. All of the 
electronic searches were restricted to English-language only. The following electronic 
databases were searched:  
 Science Direct (Elsevier) (inception to February 2012), 
 PubMed – MEDLINE (inception to November 2011), 
 The Cochrane Central Register of Controlled Trials (CENTRAL) (inception to November 
2011), 
 Web of Science (ISI) (inception to November 2011), 
 EBSCOhost  
 Academic Search Premier and CAB abstracts (inception to February 2012), 
 CINAHL (inception to November 2011), 
 Scopus (inception to November 2011), 
 Wiley Online Library (inception to February 2012), 
 SpringerLink (inception to February 2012), and 
 Google Scholar (inception to February 2012) 
2.5.2. Keywords for the Searches (Search String): 
 Term to search for the health condition: [‗statin‘ OR ‗HMG CoA Reductase Inhibitor‘ OR 
‗atorvastatin‘ OR ‗fluvastatin‘ OR ‗lovastatin‘ OR ‗pravastatin‘ OR ‗rosuvastatin‘ OR 
‗simvastatin‘] AND [‗myopathy‘ OR ‗myalgia‘ OR ‗rhabdomyolysis‘ OR muscle* OR 
muscular*] 
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 Term to search for the intervention: ‗Coenzyme Q10‘ OR ‗CoQ10‘ OR ‗Q10‘ OR 
‗Ubiquinone‘ OR ‗Ubidecarenone‘ 
 Term to search for the study design (not applicable to CENTRAL): random* AND 
control* 
2.5.3. Searching Other Resources   
Hand searches of reference lists of included RCTs were performed. Unpublished trials were 
requested from various CoQ10 manufacturers. However, none were provided. 
2.6. DATA COLLECTION AND ANALYSIS   
2.6.1. Selection of Studies   
WP conducted the initial search for studies using the relevant electronic databases and 
search strings. LP assisted with conducting the second search and tabulated the citation list 
of titles and abstracts retrieved. An independent reviewer (JK) assisted LP to examine study 
titles and abstracts to remove studies that were irrelevant according to the predetermined 
selection/eligibility criteria (Table 2.1). JK was trained in systematic review methodology and 
the background of the current review; including the application of phase 1 and 2 criteria in 
order to determine which studies were relevant for inclusion in the review. After possibly 
eligible studies had been listed in phase 1 of the selection process, the full texts were 
retrieved by LP. 
Multiple reports of the same study were linked together and duplicate records were removed 
by LP. These were identified by looking for the same authors in different order, similar 
inclusion and exclusion criteria, reports of studies done with the same name or acronym, in 
the same place, at the same time, as well as via results tables that look familiar. The full text 
reports were then scrutinized by LP and JK to assess which studies complied with the 
eligibility criteria (Table 2.1) in phase 2 of the selection process. If not, they were listed 
together with reason/s for exclusion (Table 3.5).  Disagreements on inclusion/exclusion in 
phase 1 and 2 selection were resolved through discussion and consensus data. Arbitration by 
a third person was not required. 
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Table 2.1: Phase 1 and phase 2 eligibility criteria 
Phase 1 Criteria: Liberal screening of titles and 
abstracts 
Phase 2 Additional Criteria: Application to full texts 
Inclusion Criteria 
 Human subjects on CoQ10 supplementation 
as well as statin therapy, which includes all 
registered oral HMG CoA reductase inhibitors 
(i.e. atorvastatin, fluvastatin, lovastatin, 
pravastatin, rosuvastatin and simvastatin) 
 There was a control group 
 English language studies 
 Participants were experiencing symptoms of myopathy 
identified by muscular weakness, pain and/or cramps that 
are caused by statin therapy 
 The statin therapy was taken in any prescribed dosage for 
any duration 
 The control was a placebo, similar antioxidant or no 
intervention 
 The efficacy of CoQ10 supplementation in statin-induced 
myopathy was measured by improvement in symptoms of 
myopathy and/or plasma CK levels 
 The participants were human adults (mean of 18-64.99 
years)
174
 
 Patients used CoQ10 supplementation and the control in 
addition to their usual medication 
 Randomised controlled trials (RCTs) 
Exclusion Criteria 
 The combination of CoQ10 as an intervention 
with other supplements or medication 
 Animal studies 
 No control group 
 Non-randomised controlled trials 
 Unavailable full text of the report 
 Participants with clinical evidence of other serious medical 
conditions such as hepatic, renal or endocrine disease 
2.6.2. Data Extraction and Management   
Data extraction forms (Addendum A) were developed following the Cochrane Collaboration‘s 
checklist of items for selecting studies and collecting data detailing the study source, 
eligibility, methods, participants, interventions, outcomes, results and other miscellaneous 
points such as references to other relevant studies.175 The forms were piloted by JK using a 
representative sample of the studies to be reviewed – two RCTs were randomly selected from 
the list of included studies for this purpose. JK was trained in using the data extraction form. 
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PI: Principal Investigator, IR: Independent Reviewer 
Figure 2.1: Flow diagram detailing the process of selection of studies  
List of relevant excluded studies 
Examine titles & abstracts to remove irrelevant 
reports (PI) 
Remove duplicate records of the same 
study (PI) 
Examine full texts for compliance of 
studies with eligibility criteria (PI&IR) 
Retrieve full texts of potentially relevant 
reports (PI) 
List of included studies 
Seek guidance from a healthcare 
librarian (PI) 
Conduct search 
(PI& librarian) 
No full text 
available 
Exclusion of 
study 
Second screening applying specified eligibility 
criteria (PI&IR) 
Data extraction & assessment 
of risk of bias (PI&IR) 
Meta-analysis (PI) 
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Data was extracted by LP and JK from the full text of published reports and, where possible 
by contacting the original researchers via electronic mail for missing data or additional 
information regarding methodology used. LP and JK extracted the data in a blinded fashion. 
Disagreement was resolved through discussion and consensus data. Arbitration by a third 
person was not required.  
2.6.3. Assessment of Risk of Bias in Included Studies   
The assessment of risk of bias form (Table 2.2) was adapted from the Cochrane 
Collaboration‘s tool for assessing risk of bias in included studies.176 This was a two-part tool 
addressing the following six domains of methodological design: sequence generation, 
allocation concealment, blinding, incomplete outcome data, selective outcome reporting and 
‗other sources of bias‘. The first part of the tool involved a description of what was reported to 
have happened for each domain. Where appropriate, the description of methodology was 
quoted by LP and JK from the published full text report and/or from e-mail correspondence 
with the original researcher. The second part of the tool assigned a judgment given by LP and 
JK relating to the risk of bias for that domain. A question regarding the methodology of each 
included study for each domain was indicated on the risk of bias form to ease the judgment of 
LP and JK respectively. A judgment of ‗yes‘ (low risk of bias), ‗no‘ (high risk of bias) or 
‗unclear‘ (insufficient detail is reported to make a judgment) was given for each domain.  
 
LP and JK piloted the tool prior to assessment for the risk of bias to ensure that criteria were 
applied consistently and that consensus could be reached. Representative samples of studies 
were reviewed - two RCTs were randomly selected from the list of included studies for this 
purpose. The risk of bias form adapted by LP and JK can be seen in Addendum B. 
 
The risk of bias was assessed by LP and JK in a blinded fashion. Disagreements in risk 
assessment were resolved through discussion and consensus. Arbitration by a third person 
was not required. 
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Table 2.2: Example of the Cochrane Collaboration‘s tool for assessing risk of bias 
Domain Description Review Author’s Judgment 
Sequence 
generation 
 
 
 
 
 
 
 
 
 
 
The methods used for 
sequence generation 
  
  
  
  
  
  
  
  
  
  
Was the allocation sequence adequately generated? 
 
Unclear (unclear or unknown risk of bias): 
 Insufficient information  
 
No (high risk of bias): 
 Odd or even date of birth 
 Date/day of admission 
 Hospital or clinic record number 
 Allocation by judgment of physician 
 Allocation by preference of participant 
 Allocation based on the result of a laboratory test 
 Allocation by availability of intervention 
Yes (low risk of bias): 
 Random number table 
 Coin tossing 
 Computer random number generator 
 Shuffling cards or envelopes 
 Throwing dice 
 Drawing of lots 
 Minimization 
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Domain Description Review Author’s Judgment 
Allocation 
concealment 
 
 
 
 
 
 
 
 
 
The allocation sequence 
method used 
  
  
  
  
  
  
  
  
  
Was the allocation sequence method used sufficient to conceal 
the intervention allocations? 
 
Unclear (unclear or unknown risk of bias): 
 Insufficient information (method not described) 
 
No (high risk of bias): 
 Using an open random allocation schedule (e.g. a list of random 
numbers) 
 Assignment envelopes were used without appropriate 
safeguarding (e.g. unsealed, non-opaque, non-sequentially 
numbered) 
 Alternation or rotation 
 Date of birth 
 Case record number 
 Any other unconcealed method 
 
Yes (low risk of bias): 
 Central allocation (telephone, web-based and pharmacy-
controlled randomization) 
 Sequentially numbered drug containers of identical appearance 
 Sequentially numbered, opaque, sealed envelopes 
Blinding of 
participants, 
personnel and 
outcome assessors 
 
 
 
 
 
 
 
 
 
 
Describe all measures 
used  
  
  
  
  
  
  
  
  
  
  
  
  
Was knowledge of the allocated intervention adequately 
prevented during the study? 
 
Unclear (unclear or unknown risk of bias):  
 Insufficient information 
 
No (high risk of bias): 
 No/incomplete blinding, and the outcome or outcome 
measurement is likely to be influenced by lack of blinding 
 Blinding attempted but may have been broken 
 Participants/key study personnel were not blinded, and the non-
blinding of others likely to introduce bias 
 
Yes (low risk of bias): 
 No blinding - but the outcome and the outcome measurement 
are not likely to be influenced by lack of binding  
 Blinding of participants and key study personnel ensured, and 
unlikely that the blinding could have been broken 
 Either participants or some key study personnel were not  
blinded, but outcome assessment was blinded and the non-
blinding of others unlikely to introduce bias 
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Domain Description Review Author’s Judgment 
Selective outcome 
reporting 
 
 
 
Describe how selective 
outcome reporting was 
examined and findings? 
  
  
Are reports of the study free of suggestion of selective 
outcome reporting? 
 
Unclear (unclear or unknown risk of bias): 
 Insufficient information 
 Study did not address the outcome 
 
No (high risk of bias): 
 Not all pre-specified primary outcomes have been reported 
 One or more primary outcome is reported using measurements, 
analysis methods or subsets of data that were not pre-specified 
 One or more reported primary outcomes were not pre-specified 
(unless justification is provided) 
 One or more outcomes of interest are reported incompletely  
 Study fails to include results for a key outcome that would be 
expected to have been reported 
 
Yes (low risk of bias):  
 Study protocol is available, primary and secondary outcomes 
are reported in the pre-specified way 
 Study protocol is not available, but it is clear that the published 
reports include all expected outcomes, including those that were 
pre-specified 
Other sources of 
bias 
Other sources of bias 
not addressed by other 
domains 
Was the study free of other sources of bias? 
 
Unclear (unclear or unknown risk of bias): 
 Insufficient information 
 Insufficient rationale or evidence that the identified problem will 
introduce bias 
 
No (high risk of bias): 
 Potential source of bias related to the study design 
 Study stopped early due to some data-dependent process 
 Extreme baseline imbalance 
 Study is claimed to be fraudulent 
 Any other problem 
 
Yes (low risk of bias): 
 Free of other sources of bias 
 
Source: Cochrane Handbook for Systematic Reviews of Interventions (2008)177 
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2.6.4. Data Analysis and Undertaking Meta-Analyses 
A meta-analysis was anticipated using the Cochrane review writing software (RevMan 5) to 
collate results of studies reporting on the efficacy of CoQ10 versus a comparator during statin 
therapy.  
The meta-analysis was planned to determine the direction and size of the effect and whether 
the effect is consistent across the studies. In consultation with the statistician it was, however, 
decided that a meta-analysis was not feasible as results from one of the included studies 
were expressed as means with standard deviations (SDs), and results from the other RCT 
were expressed as medians with interquartile ranges (IQRs). The results from each study 
were therefore reported separately and no data synthesis was performed. 
2.6.5. Measures of Treatment Effect   
Where possible, risk ratios (RR) would have been calculated for the dichotomous outcomes, 
namely the adverse effects of CoQ10 supplementation. Mean differences (MD) would have 
been calculated for the continuous outcomes, namely plasma CK levels, intramuscular and 
plasma CoQ10 levels as well as myopathic pain. Results were to be presented with 
corresponding 95% confidence intervals. Continuous outcomes reported as medians and 
interquartile ranges (IQR) were presented in tables. 
2.6.6. Unit of Analysis Issues   
No cluster randomised trials, cross-over trials, or trials with multiple treatment arms were 
found in the process of selection of studies, therefore no unit of analysis issues were 
encountered. 
2.6.7. Dealing with Missing Data   
The study authors were contacted via electronic mail to request relevant missing or unclear 
data. Joanna Young was contacted in October 2011 to request information regarding one 
missing participant in the results of her study. She responded that one patient did not return 
his/her diary containing visual analogue scales that documented symptoms of myalgia, which 
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resulted in his/her exclusion from the study. An intention to treat (ITT) analysis was planned 
for any data that may have been missing.  
2.6.8. Assessment of Heterogeneity   
Since a meta-analysis was not performed, no assessment of heterogeneity was done. The 
following procedure was, however, initially planned: 
A Chi-squared statistical test for heterogeneity and the I2 test would have been used across 
all included studies to quantify inconsistency (significance level P < 0.1). The importance of 
the I2 value is related to the magnitude and direction of the effects as well as the strength of 
evidence for heterogeneity, determined by the confidence interval. If heterogeneity is 
identified, the cause/s must be established and if it cannot be explained, a random-effects 
meta-analysis must be used.  
The following guidelines would have been used for the interpretation of the I2 values:178 
  
 0% to 40%: may not be important 
 30% to 60%: may represent moderate heterogeneity 
 50% to 90%: may represent substantial heterogeneity 
 75% to 100%: considerable heterogeneity 
 
Possible sources of heterogeneity would have been explored further through the following 
sub-groups in data-analysis: 
 
 Different measurement tool/s for myopathy between studies 
 Different statin use in participants (simvastatin, atorvastatin, pravastatin, fluvastatin or 
lovastatin) 
 Varying statin dosages in participants (low dose vs. high dose) 
 Different duration of intervention between studies 
 Varying CoQ10 supplementation dosages (low dose vs. high dose) in participants 
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2.6.9. Assessment of Reporting Biases   
Reporting bias include publication, time lag, multiple publication, location, citation, language 
and outcome reporting biases. Detecting reporting biases can be done by means of funnel 
plots. These can, however, only be used if there are more than 10 studies included in the 
meta-analysis.179 Since there were only two included studies and a meta-analysis was not 
performed as planned, no assessment of reporting biases was done. 
2.6.10. Data Synthesis   
A meta-analysis was planned to summarize the effectiveness of the experimental intervention 
by using Cochrane review writing software (RevMan 5). The random-effects method of meta-
analysis would have been used on the assumption that the different studies estimated 
different, yet related, intervention effects. 
2.6.11. Subgroup Analysis and Investigation of Heterogeneity   
A subgroup analysis on the dose or duration of CoQ10 supplementation and/or statin therapy 
was planned using RevMan but was not feasible as a meta-analysis was not performed. A 
subgroup analysis could have been conducted on participant gender and/or statin dose, 
although statin dose may have been more relevant as a higher dose may increase patient risk 
to symptoms of myopathy. 
2.6.12. Sensitivity Analysis   
No sensitivity analysis was done because a meta-analysis was not performed as planned. 
2.7. ETHICS/LEGAL ASPECTS/REGISTRATION INFORMATION 
Ethics approval was obtained in March 2011, ethical review was not required as the study is a 
systematic review. Ethics Reference number: N11/03/087 (Addendum C).  
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CHAPTER 3:  RESULTS 
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3.1. RESULTS OF THE SEARCHES   
Two searches for studies were conducted as a considerable period of time passed between 
the initial search and the commencement of the review. The initial searches took place 
between March and April 2011 (Table 3.1), and the second searches took place between 
November 2011 and February 2012 (Table 3.2). The initial and second searches were 
completed independent of each other, and were each dated from inception. Both searches 
used the same databases and search strings. The aim of the second searches, however, was 
to identify any new records additional to those found in the initial searches. Thus, if the same 
records were found after the removal of duplicates and as well as after the screening of titles 
and abstracts, they were excluded. Duplicates of studies were defined as the repetition of a 
record across the 11 databases searched in the initial and second searches respectively.  
3.1.1. Initial Searches 
From 11 databases (section 3.3.1), 474 records were cited. The abstracts of the studies of 
Kelly et al (2005)190 and Fedako (2009)181 were identified by means of hand-searching. After 
the removal of duplicate records, 353 records remained. After screening of the 353 titles and 
abstracts (phase 1, Table 2.1), only 5 records remained. Five full texts were retrieved for 
further evaluation according to eligibility criteria (phase 2, Table 3.1), however only 2 studies 
met the inclusion criteria and were included in the qualitative and quantitative synthesis. 
3.1.2. Second Searches 
From 11 databases, 951 records were retrieved. After the removal of duplicate records, 864 
records remained. After screening of the 864 titles and abstracts (phase 1, Table 2.1), no 
records, additional to initial search outcome, were identified. The second search for studies 
thus did not identify any new studies for inclusion in the review. 
Adaptations to the search string were done specifically to ensure that the maximum numbers 
of studies were found in the respective databases. The original search string was adapted in 
the March 2011 search in Scopus, as well as the March/April 2011 and February 2012 
searches in the Wiley Online Library as well as SpringerLink (as shown in Tables 3.1 and 
3.2). 
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Table 3.1: Citation list of titles and abstracts retrieved from database searches between 
March and April 2011 
Database 
Date 
searched 
Search string 
Total number 
retrieved to be 
screened 
PubMed 
Inception to 
29/03/2011 
(Statin OR HMG CoA Reductase Inhibitor OR 
Atorvastatin OR Fluvastatin OR Lovastatin OR 
Pravastatin OR Rosuvastatin) and (Myopathy OR 
Myalgia OR rhabdomyolysis OR muscle* OR 
muscular) and (coenzyme Q10 OR CoQ10 or Q10 
OR Ubiquinone OR Ubicarenone) 
36 
Web of 
Knowledge 
78 
Cochrane Library 12 
CINAHL 7 
Academic Search 
Premier 
10 
CAB Abstracts 2 
Google Scholar 148 
ScienceDirect 59 
Scopus 
(coenzyme* Q10) AND supplement* AND (treat* 
OR therap* OR manage*) AND (statin-induced 
myopathy) AND (clinical trial* OR randomised 
control* trial*) 
72 
Wiley Online 
Library (coenzyme Q10) in All Fields AND supplement* in 
All Fields AND treatment in All Fields AND (statin-
induced myopathy) in All Fields 
32 
SpringerLink 
Inception to 
05/04/2011 
18 
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Table 3.2: Citation list of titles and abstracts retrieved from database searches between 
November 2011 and February 2012  
Database 
Date 
searched 
Search string 
Total number 
retrieved to be 
screened 
PubMed 
Inception to 
14/11/2011 
(statin OR HMG CoA reductase inhibitor OR 
atorvastatin OR fluvastatin OR lovastatin OR 
pravastatin OR rosuvastatin) AND (myopathy 
OR myalgia OR rhabdomyolysis OR muscle* OR 
muscular) AND (coenzyme Q10 OR CoQ10 OR 
Q10 OR ubiquinone OR ubidecarenone) 
19 
Web of 
Knowledge 
44 
Cochrane Library 3 
CINAHL 8 
Academic Search 
Premier 
Inception to 
15/02/2012 
10 
CAB Abstracts 12 
Google Scholar 665 
ScienceDirect 33 
Scopus Inception to 
14/11/2011 
102 
Wiley Online 
Library 
Inception to 
15/02/2012 
(coenzyme Q10) in All Fields AND supplement* 
in All Fields AND treatment in All Fields AND 
(statin-induced myopathy) in All Fields 
37 
SpringerLink 18 
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Figure 3.1: Flow diagram detailing the searches for studies 
Number of additional 
records identified 
through other sources: 2 
(hand searches) 
Number of records identified 
through database searching: 
Initial searches: 474 
Second searches: 951 
Number of records 
screened (Phase 1): 
Initial searches: 353 
Second searches: 864 
Number of full text 
articles retrieved and 
assessed for eligibility 
(Phase 2): 
Initial searches: 5 
Second searches: 0 
Number of studies 
included in qualitative 
synthesis: 
Initial searches: 2 
Second searches: 0 
Number of studies included in 
quantitative synthesis (meta-analysis): 
Both searches: 0 
Number of records 
excluded (Phase 1): 
Initial searches: 348 
Second searches: 864 
Number of full texts 
excluded with reasons 
(Phase 2): 
Initial searches: 3 
Second searches: 0 
Number of records 
after duplicates 
removed: 
Initial searches: 353 
Second searches: 864 
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3.2. DESCRIPTION OF STUDIES 
 
3.2.1. Included Studies 
Two RCTs [Caso (2007)70 and Young et al (2007)27] met all of the inclusion criteria. The 
characteristics of these two studies are summarized in Table 3.6. 
3.2.1.1. Study Types 
Caso (2007)70 conducted a double-blind, randomised, controlled trial and Young et al (2007)27 
a double-blind, placebo-controlled pilot study. 
3.2.1.2. Participants 
Participants were aged 59 +2 years in the intervention and control groups in the study of 
Young et al (2007)27, and 58 +2 years and 64 +2 years in the control and intervention groups 
respectively in the study of Caso (2007)70. Participants in both included studies were of male 
and female gender. Race/ethnic groups were not indicated in either of the studies.  
 
The participants in the study of Caso (2007)70 were treated for hyperlipidemia with different 
types of statins (Table 3.3) at varying doses (Table 3.4) and were under the Adult Treatment 
Panel III/National Cholesterol Education Program. All participants reported myopathic 
symptoms. Patients were enrolled only if no other identifiable cause of myopathy could be 
determined and any patients with clinical evidence of hepatic, vascular, renal, or endocrine 
disease; coagulopathy; or other serious medical conditions were excluded. None of the 
patients enrolled in this study had been using CoQ10, vitamin E or anticoagulants before 
starting the study. The participants in the study of Young et al (2007)27 had self-reported 
myalgia and were unable to continue taking adequate doses of statin therapy. Participants 
were using only simvastatin titrated from 10 mg/day to 40 mg/day in 4-weekly intervals. 
Patients were not enrolled if an acute myocardial infarction or cerebral vascular accident had 
been experienced within the previous 3 months, if alanine aminotransferase or aspartate 
aminotransferase were >3 times the upper level of normal, if calculated glomerular filtration 
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rate was <45 ml/min, if the patient had decompensated heart failure, was treated with 
warfarin, and if the patient was using antioxidant vitamin supplementation. 
 
Table 3.3: Statin types used in the study of Caso (2007)70 
 
Table 3.4: Statin doses used in the study of Caso (2007)70 
 
 
3.2.1.3. Interventions 
CoQ10 was the intervention used in both included studies. The CoQ10 supplements were 
taken once daily, however, neither of the studies indicated the method of administration of 
CoQ10, so it is unknown at what time of the day (and relation to meal times) the supplements 
were taken, whether they were in capsule or powder form, or whether they were mixed or 
swallowed with a particular beverage (e.g. water or fruit juice). 
Type of statin used No. patients in the CoQ10 
group (n=18) 
No. patients in the control 
(Vitamin E) group (n=14) 
Atorvastatin 4 3 
Lovastatin 1 0 
Pravastatin 2 0 
Simvastatin 11 11 
Statin dose (mg/day) No. patients in the CoQ10 
group (n=18) 
No. patients in the control 
(Vitamin E) group (n=14) 
10 to 20  9 9 
>40 9 5 
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3.2.1.4. Controls 
The control used in the study of Caso (2007)70 was in the form of Vitamin E, which served to 
control for the antioxidant properties of CoQ10, and was also similar in appearance. The 
control in the study of Young et al (2007)27 is in the form of a placebo. 
3.2.1.5. Funding 
The study of Caso (2007)70 was supported in part by a grant from the National Institutes of 
Health, Bethesda, Maryland, and the New York State Empire Clinical Research Investigator 
Program, Albany, New York. Joanna Young was contacted via electronic mail to obtain 
information regarding the funding of the study; however a response was not received. 
3.2.1.6. Measurement Tools for Myopathy 
In the study of Caso (2007)70, symptoms of myopathy were defined as the presence of 
muscle pain alone or accompanied by other symptoms such as muscle weakness and 
fatigue. Symptoms of myopathy and their interference with patients‘ daily activities were 
evaluated before and after the intervention using the BPI questionnaire (Table 3.5). It includes 
a body diagram for localization of pain, 4 items to measure pain intensity in the previous 24 
hours (―pain worst,‖ ―pain least,‖ ―pain average,‖ and ―pain now‖) rated on a numeric scale of 0 
to 10 (i.e., 0 = ―no pain‖ and 10 = ―pain as bad as you can imagine‖), and 7 items measuring 
pain interference with daily life in the previous 24 hours (i.e., general activity, mood, walking, 
working, relations with others, sleeping, and enjoyment of life), also rated on a 0 to 10 scale 
(i.e., 0 = ―does not interfere‖ and 10 = ―completely interferes‖). Pain intensity was assessed by 
calculating a PSS, computed by averaging scores of the 4 pain intensity items. Similarly, the 
impact of pain on daily living activities and well-being was assessed by calculating a PIS, 
obtained by averaging ratings of the 7 interference items. 
In the study of Young et al (2007)27, severe myalgia was defined as the inability to tolerate a 
statin dose of 20 to 40 mg/day within 1 month of commencement, and moderate myalgia was 
defined as the development of myalgic symptoms at doses >20 mg/day after more than 1 
month. The VAS (Table 3.5), which was used to measure myopathy, was adapted from 
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Landstad (2001)182, which is a descriptive study of the occurrence of pain in hospital cleaners 
and home-help personnel. The questionnaire used in Landstad (2001)182 contained questions 
about the frequency of pain and rating of perceived intensity of pain [VAS for ―worst‖, ―least‖ 
and ―present‖ pain were used]. The subjects indicated the location of their pain on diagrams 
(Figure 3.2), and categorization was based on the number of subjects (percentage) who had 
made a pain mark in each area of the body. These frequency intervals were evenly divided 
into 1–18%, 19–36%, 37–54% and 55–72%, plus a zero category. Twenty-three areas were 
combined to constitute the neck–shoulder–upper extremity region, nine areas constituted the 
lumbosacral spine–thigh region and 12 areas constituted the knee–lower leg–foot region. The 
intensity of pain was measured using a pain scale from 0mm (no pain) to 100mm (worst pain).  
 
 
 
 
Twenty-three areas were combined - categorisation was based on the number of subjects 
who made a mark in each area.  
Figure 3.2: Example of a diagram for self-administered location of pain 
Source: Landstad (2001)182 
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Table 3.5: Measurement tools for myopathy in the study of Caso (2007)70 and Young et al 
(2007)27 
 Brief Pain Inventory  
Caso (2007)70 
Visual Analogue Scale  
Young et al (2007)27 
Frequency of assessment At baseline and after the 
intervention 
Daily 
Method of administration Self-administered Self-administered 
Scales used  Pain intensity (0=‖no 
pain‖ to 10=‖pain as bad 
as you can imagine‖) 
 Pain interference with 
daily activities (0=‖no 
interference‖ to 
10=‖completely 
interferes‖)  
Pain Intensity (0-100mm) 
Particulars measured  Localization of pain (a 
body diagram is given 
for indication) 
 Pain interference with 
daily activities (e.g. 
mood, walking and 
sleeping) (PIS) 
 Pain severity (PSS) 
 Number of sites on the body 
that are affected 
 Pain intensity (mm) 
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Table 3.6: Particulars of studies included in the review 
 
3.2.2. Excluded Studies 
Abstracts of two RCTs180,181 complied with phase 1 eligibility criteria.  Unfortunately the full 
text reports of these two studies could not be sourced, which excluded them from the review. 
The summary of these two abstracts in Table 3.7 shows that they may have been relevant for 
inclusion in this review. Three studies were excluded from the review due to reasons relating 
to study design and outcomes measured (Table 3.8).172,183,184 
Study Intervention Control Participants Methods Evaluation of 
myopathy 
Outcomes 
Caso 
(2007)
70 
CoQ10  
(Q-Sorb 
softgel), 
100mg once 
daily 
Vitamin E 
(softgel), 
400IU once 
daily 
32 male and 
female adult (59 
+ 2 years in 
intervention and 
control group) 
outpatients 
(ethnicity not 
indicated), Stony 
Brook University, 
New York  
RCT, 30 
days 
Brief Pain 
Inventory 
questionnaire. 
Pain intensity 
assessed by 
calculating a 
Pain Severity 
Score (PSS) 
To determine whether 
CoQ10 
supplementation 
would reduce the 
degree of muscle pain 
associated with statin 
treatment. 
Pain severity and 
interference with daily 
activities were 
reported 
Young et 
al 
(2007)
27 
CoQ10  
(Q-Gel), 
200mg once 
daily 
Placebo 44 male and 
female adult (58 
+ 3 years in 
intervention 
group; 64 +2 
years in control 
group) 
outpatients 
(ethnicity not 
indicated), New 
Zealand 
RCT, 12 
weeks 
Visual analogue 
scale adapted 
from Landstad et 
al., intensity of 
pain rated 0 (no 
pain) to 100 
(worst pain) 
measured daily, 
no. of sites 
affected 
No. of patients who 
tolerated simvastatin 
40mg/day at 12 
weeks, no. of patients 
remaining on 
simvastatin therapy 
and change in myalgia 
scores 
Stellenbosch University http://scholar.sun.ac.za
  - 53 - 
Table 3.7: Particulars of studies with no available full text 
Study Intervention Control Participants Methods Evaluation of 
myopathy 
Outcomes 
Kelly et al 
(2005)
180 
CoQ10, 100mg 
daily 
Vitamin E, 
400IU once 
daily 
41 patients, 
University of 
Wisconsin 
RCT, 30 
days 
Pain score Mean pain scores 
are reported 
Fedako 
(2009)
181 
CoQ10 (dose 
not indicated) 
vs. placebo 
Selenium 
vs. placebo 
60 patients, single 
centre, Kosice 
(Slovakia) 
Double-
blind RCT, 
2x2 
factorial 
design, 3 
months 
Reported 
symptoms: pain, 
muscle 
weakness, 
tiredness and 
cramps 
Change in plasma 
CoQ10 and 
improved symptoms 
of statin-associated 
myopathy are 
reported  
In the study of Langsjoen (2005)172 patients on statin therapy were evaluated for possible 
adverse effects, including myalgia and fatigue, amongst other. The prevalence of patient 
symptoms on initial visit and on most recent follow-up (an average of 22.4 months later) 
demonstrated a decrease in fatigue from 84% to 16%, and myalgia from 64% to 6%. Although 
the study explored the efficacy of CoQ10 for side effects of statins, including myalgia, the 
study is not a RCT and statin therapy was discontinued when CoQ10 supplementation 
commenced (two simultaneous interventions) – the predominant reasons for exclusion of the 
study in the review. 
The study of Glover et al (2010)183 was on patients with mitochondrial disease recruited from 
the Neuromuscular/Neurometabolic Clinic at McMaster University Medical Centre. Although 
plasma CoQ10 and CK were measured, main outcomes related to CoQ10 and cycle 
ergometry (V02 and lactate), magnetic resonance spectroscopy (MRS), activities of daily living 
(ADL) and quality of life (QOL). The study was excluded from the review as the said 
mitochondrial disorders were not statin-induced and benefits of CoQ10 related to exercise 
performance, not symptoms of myopathy. 
 
The study of Mabuchi et al (2007)184 examined the effects of CoQ10 and placebo in the 
hypercholesterolaemic patient treated with atorvastatin. Adverse effects were recorded 
throughout the treatment phase. Unfortunately outcomes of the study were not related to the 
side effects of statin use: changes in total cholesterol, plasma LDL-C levels, serum 
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triglycerides, apolipoprotein A1 and B, as well as plasma total CoQ10, ubiquinol-10 and 
ubiquinone-10 were measured. No complaints of myalgia or muscle weakness were found, 
which is the main area of interest in the current review. Although the study is a RCT, the main  
reason for exclusion is because patients were not experiencing symptoms of myopathy at 
baseline.  
 
Table 3.8: Particulars of studies excluded from the review 
Study Intervention Control Participants Methods Outcomes Reasons for 
exclusion 
Langsjoen 
(2005)
172 
CoQ10, 240mg 
once daily 
No control 50 male and 
female adult and 
elderly (44-84 
years, mean 
age of 66 years) 
outpatients, 
Texas USA 
Prospective 
analysis, 
average of 
22.4 months 
follow-up 
(between 2 
and 41 
months) 
Prevalence 
of statin 
adverse 
effects were 
reported 
 Not a RCT 
 Patients‘ mean 
age was not 
between 18 and 
64.99 years 
 Efficacy of 
CoQ10 not 
measured 
 Patients not 
experiencing 
myopathic 
symptoms at 
baseline 
Glover et al 
(2010)
183 
CoQ10  
(Q-Gel), 600mg 
twice daily 
Placebo 
(soybean 
oil) 
30 male and 
female adults 
(48+3 years in 
MELAS group; 
56+3 years in 
the control 
group), Canada 
Double-blind, 
placebo-
controlled 
cross over 
study, 60 
days with 
mean 67 + 
8.3 days 
washout 
between 
trials 
Cycle 
exercise 
aerobic 
capacity, 
post-exercise 
lactate, 
resting 
lactate and 
strength were 
reported 
 Patients not 
experiencing 
myopathic 
symptoms 
 Patients not on 
statin therapy 
Mabuchi et 
al (2007)
184 
CoQ10, 100mg 
once daily 
Placebo 
(safflower 
oil) 
49 male and 
female adult and 
elderly (60+8 
years in 
intervention 
group; 61+8 
years in control 
group) 
outpatients, 
Japan 
RCT, 12 
weeks 
Effect of 
Atorvastatin 
on plasma 
CoQ10, AST, 
ALT and CK 
were 
reported 
 Patients not 
experiencing 
myopathic 
symptoms 
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3.3. RISK OF BIAS IN INCLUDED STUDIES   
The Cochrane Collaboration‘s tool for assessing risk of bias in included studies was used to 
assess the risk of bias.185 The two-part tool addressed the following six domains of 
methodological design: sequence generation, allocation concealment, blinding, incomplete 
outcome data, selective outcome reporting and ‗other sources of bias‘. 
 
 3.3.1. Sequence Generation 
 
In the study of Caso (2007)70, randomization of the dispensing of supplements was carried 
out by the pharmacist without contact with the patients – sequence generation was thus 
adequate. In the study of Young et al (2007)27, randomization was performed in permutation 
blocks of size-6 from a computer-generated randomization list by an independent statistician - 
sequence generation was thus also adequate. 
3.3.2. Allocation Concealment 
In the study of Caso (2007)70, allocation concealment is adequate as the pharmacist from the 
research centre who dispensed the supplements did not have contact with the patients. In the 
study of Young et al (2007)27, study treatments were dispensed by an independent hospital 
pharmacist in identical numbered bottles, with the lowest available number allocated to each 
sequential participant. Allocation concealment was thus also adequate. 
 
3.3.3. Blinding 
 
In the study of Caso (2007)70, adequate blinding of the study was confirmed: ―randomization 
and dispensing of supplements was carried out by the pharmacist at the General Clinical 
Research Centre at Stony Brook University without direct contact with patients, and patients 
as well as investigators were blinded throughout the protocol to which supplement was 
administered to whom‖. The study of Young et al (2007)27 is double-blinded – identically 
matched placebo and CoQ10 capsules were used and no access to the CoQ10 results were 
allowed until the study was un-blinded.  
Stellenbosch University http://scholar.sun.ac.za
  - 56 - 
3.3.4. Incomplete Outcome Data 
 
No incomplete outcome data was identified in the study of Caso (2007)70. In the study of 
Young et al (2007)27, only one patient‘s results were not reported. Details from author 
correspondence confirmed that this patient did not return his/her diary containing visual 
analogue scales that documented myalgia symptoms – no re-inclusions in the analyses were 
performed by the review authors.  
 
3.3.5. Selective Outcome Reporting 
 
The studies of Caso (2007)70 and Young et al (2007)27 are free of selective outcome 
reporting.  
 
3.3.6. Other Sources of Bias 
 
No other sources of bias were identified. 
 
In summary, the study of Caso (2007)70 has mostly a low risk of bias as risk of bias was low 
for six of the seven domains (Figure 3.3 and 3.4, Table 3.9).  In the study of Young et al 
(2007)27, information regarding the risk of bias was obtained via author correspondence. This 
study has mostly a low risk of bias as risk of bias was low for six of the seven domains (Figure 
3.3 and 3.4, Table 3.10). Blinding of outcome assessment was unclear for both studies, which 
may introduce detection and/or performance bias. 
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Table 3.9: Risk of bias in the study of Caso (2007)70 
 
Judgement:  
Yes (low risk of bias)/ 
No (high risk of bias)/ 
Unclear 
Description 
Adequate Sequence 
Generation 
Yes  
Quote: ―randomization and dispensing of supplements was 
carried out by the pharmacist at the General Clinical 
Research Centre at Stony Brook University without direct 
contact with patients‖ 
Comment: the key word here is ―randomization‖ 
Adequate Allocation 
Concealment 
Yes 
Quote: ―randomization and dispensing of supplements was 
carried out by the pharmacist at the General Clinical 
Research Centre at Stony Brook University without direct 
contact with patients‖ 
Blinding of 
participants and 
personnel 
Yes 
Quote 1: ―double-blind randomised study‖ 
Quote 2: ―patients as well as investigators were blinded 
throughout the protocol to which supplement was 
administered to whom‖ 
Blinding of outcome 
assessment 
Unclear Insufficient information given 
No Incomplete 
Outcome Data 
Yes All outcome data reported in study results 
No Selective 
Outcome Reporting 
Yes All outcomes reported in study results 
Other sources of 
bias 
Yes No other sources of bias detected 
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Table 3.10: Risk of bias in the study of Young et al (2007)27 
 
Judgement:  
Yes (low risk of bias)/ 
No (high risk of bias)/ 
Unclear 
Description 
Adequate Sequence 
Generation 
Yes 
Quote from author correspondence: ―randomization was 
performed in permutation blocks of size-6 from a computer-
generated randomization list by an independent statistician‖ 
Adequate Allocation 
Concealment 
Yes 
Quote from author correspondence: ―study treatments were 
dispensed by an independent hospital pharmacist in identical 
numbered bottles, with the lowest available number allocated 
to each sequential participant.‖ 
Blinding of 
participants and 
personnel 
Yes 
Quote: ―double-blinded, placebo-controlled pilot study‖ 
Quote from author correspondence: ―identically matched 
placebo and CoQ10 capsules were used and no access to the 
CoQ10 results were allowed until the study was unblinded‖ 
Blinding of outcome 
assessment 
Unclear Insufficient information given 
No Incomplete 
Outcome Data 
Yes All outcome data reported in study results 
No Selective 
Outcome Reporting 
Yes All outcomes reported in study results 
Other sources of 
bias 
Yes No other sources of bias detected 
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Figure 3.3. Risk of bias summary: review authors' judgments about each risk of bias item for 
Caso (2007)70 and Young et al (2007)27 
 
Figure 3.4. Risk of bias graph: review authors' judgments about each risk of bias item 
presented as percentages 
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3.4. EFFECTS OF INTERVENTIONS 
3.4.1. Primary Objectives 
3.4.1.1. The severity of statin-induced myopathic symptoms 
The study of Caso (2007)70 evaluated myopathic pain using the BPI questionnaire before and 
after treatment and rated pain intensity on a VAS of 0 (no pain) to 10cm (worst pain). Results 
were reported in terms of PSS, which is the average of pain intensity scores of the four pain 
intensity items. Supplementation with CoQ10 significantly improved the severity of myopathic 
pain compared to the control group, as measured by the change in PSS after minus before 
supplementation (MD 2.37, 95%CI: 1.29 to 3.45, 1 trial, 32 participants, Figure 3.5, Table 
3.11). Significantly more participants in the CoQ10 group reported pain relief compared to the 
control group (RR 4.15, 95%CI: 1.50 to 11.46, 1 trial, 32 participants, Figure 3.6). Pain relief 
included a decrease in pain, ache, burning sensation and overall muscle fatigue. The authors 
concluded that these findings suggest that CoQ10 may be beneficial for patients using statins 
by ameliorating myopathic symptoms and improving subject‘s well-being and functioning in 
daily life activities. 
 
Figure 3.5: Forest plot of the comparison of CoQ10 versus controls for severity of myopathic 
symptoms 
 
Figure 3.6: Forest plot of the comparison of CoQ10 versus controls for the number of 
participants reporting decrease in pain 
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The study of Young et al (2007)27 assessed myalgia daily using a VAS of 0 (no pain) to 
100mm (worst pain) adapted from Landstad (2001)182 and reported the change in these 
myalgia scores. The study authors reported that although there were significant increases in 
myalgia score from baseline to the end of study for both the CoQ10 and placebo groups, 
there were no significant differences in changes between the two groups (p=0.63, 43 
participants, 1 trial, Table 3.12). When adjusted for the number of sites affected by pain, the 
pain score increased by a median (IQR) of 4.2mm (1.0 to 6.4) in the CoQ10 group and 2.1mm 
(0 to 11.4) in the control group – there remained no difference between the two groups 
(p=0.73). The authors concluded they could not demonstrate any significant beneficial effect 
of oral CoQ10 supplementation on simvastatin tolerability and myalgic symptoms in patients. 
Table 3.11: Results of intervention on pain severity score and plasma creatine kinase levels 
(Caso 2007)70 
Outcome 
Study 
ID 
Results 
Intervention (n=18) Control (n=14) 
Comment 
Baseline 
Mean 
(SD) 
Study 
End 
Mean 
(SD) 
Change 
Mean 
(SD) 
Baseline 
Mean 
(SD) 
Study 
End 
Mean 
(SD) 
Change 
Mean 
(SD) 
Pain 
Severity 
Score 
(PSS) 
Caso 
(2007)70 
5 (1.44) 
2.97 
(2.04) 
2.03 
(1.87) 
4.39 
(2.24) 
4.73 
(2.54) 
-0.34 
(1.23) 
SD=SEMx√n 
Plasma 
CK  (U/L) 
Caso 
(2007)70 
129 
(63.64) 
157 
(97.58) 
-28 
133 
(138.44) 
103 
(52.38) 
30 
SD=SEMx√n 
SD = standard deviation; SEM = Standard Error of the Mean; √n = square root of sample size 
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Figure 3.7: Forest plot of comparison of CoQ10 versus controls for plasma creatine kinase 
(U/L) 
Table 3.12: Results intervention on the myalgic scale, plasma creatine kinase and CoQ10 
levels Young et al (2007)27 
Outcome Study ID 
Results 
Intervention 
(n=22) 
Control  
(n=22) 
p-value for 
difference in 
change between 
the intervention and 
control groups 
Change 
Median (IQR) 
Change 
Median 
(IQR) 
Myalgia scale 
(0-100mm) 
Young et al 
(2007)27 
6.0 (2.1 to 8.8) 2.3 (0 to 
12.8) 
0.63 
Plasma CK 
(U/L) 
Young et al 
(2007)27 
17 (-15 to 46) 19 (-3 to 48) 0.85 
Plasma 
CoQ10 
(µmol/L) 
Young et al 
(2007)27 
1.7 (0.3 to 2.2) -0.5 (-0.6 to -
0.3) 
<0.001 
3.4.1.2. The effect of CoQ10 supplementation on plasma CK levels  
In Caso (2007) 70, plasma CK concentration (U/L) at the end of the intervention period was 
significantly higher in the CoQ10 compared to the control group (MD 54.00, 95%CI: 1.23 to 
106.77, 1 trial, 32 participants, Table 3.11, Figure 3.7). There was no correlation (data not 
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published) between the pain score and plasma CK concentration before or after the 
intervention.  
In the study of Young et al (2007)27, there was no significant difference in changes from 
baseline plasma CK levels between the CoQ10 group and the placebo group (p=0.85, 44 
participants, 1 trial, Table 3.12), no significant increase in the CoQ10 group (p=0.14), and a 
significant increase with the placebo group (p=0.02) from baseline to end of study. 
3.4.1.3. The effect of CoQ10 supplementation on intramuscular and plasma CoQ10 levels  
The study of Young et al (2007)27 reported that plasma CoQ10 (µmol/L) levels significantly 
increased after the CoQ10 supplementation (p<0.001) but significantly decreased after the 
placebo treatment (p<0.001). Further, the differences between the two groups were 
statistically significant according to the study authors (p<0.001, 44 participants, 1 trial, Table 
3.12). Intramuscular CoQ10 was not measured in this study. 
Plasma and intramuscular CoQ10 were not measured in the study of Caso (2007)70. 
3.4.1.4. Adverse effects of CoQ10 supplementation; such as abdominal pain, nausea and 
vomiting or headaches 
No adverse effects of CoQ10 were reported in either of the studies. 
3.4.2. Secondary Objectives 
3.4.2.1. The average duration of CoQ10 supplementation required to elicit a positive response 
In the study of Caso (2007)70, patient follow-up was after 30 days of intervention with CoQ10. 
By day 30, pain intensity decreased significantly in the CoQ10 group. However, in the study of 
Young et al (2007)27, patient follow-up was after 12 weeks of intervention with CoQ10. By the 
12th week, although pain scores had significantly increased (Table 3.12) in both the CoQ10 
and the control group, there were no significant changes between the two groups. Thus, 
despite the longer duration of intervention in the study of Young et al (2007)27, CoQ10 did not 
elicit a positive response. 
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3.4.2.2. The average dose of CoQ10 supplementation required to elicit a positive response 
In the study of Caso (2007)70, CoQ10 was given at 100 mg daily and elicited a positive 
response after 30 days (Table 3.11). In the study of Young et al (2007)27, CoQ10 was given at 
200 mg daily. Although the dose of CoQ10 given in the study of Young et al (2007)27 was 
higher, it did not elicit a positive response (Table 3.12). Dose-response was, however, not 
explored in the two studies.  
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CHAPTER 4:  DISCUSSION 
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4.1. SUMMARY OF THE MAIN RESULTS 
In this systematic review, two small RCTs met the inclusion criteria, which included a total of 
76 participants. A meta-analysis could not be performed as initially planned as one study 
reported results as means with SDs, and the other as medians with IQRs. The results of the 
two RCTs were conflicting, thus a conclusion could not be drawn regarding the efficacy of 
CoQ10 in statin-induced myopathy. The differences between the RCTs in terms of what they 
measured, how they measured it as well as other factors, such as the type and dose statins 
used by participants, may be reasons for the variation in results.  
Only two outcomes were considered in both of the RCTs included in the review – the 
improvement in myopathic symptoms and the change in participants‘ plasma CK 
concentration. The study of Young et al (2007)27 also measured the change in participants‘ 
plasma CoQ10. Neither RCTs measured intramuscular CoQ10, which would have been of 
value in adding to the limited data on the effect of CoQ10 supplementation on participants‘ 
intramuscular CoQ10 concentration, although this measurement may be regarded as an 
invasive procedure. No adverse effects of CoQ10 supplementation were reported between 
the two RCTs, which was expected as doses up to 3000 mg/day have been reported as safe 
and were tolerated in other study populations.132,155  
Dose and duration were not investigated in the included RCTs. Despite the longer study 
duration and higher dose of CoQ10 supplemented in the study of Young et al (2007)27, 
myalgia significantly increased in both groups (intervention and control). In the study of 
Bhagavan (2006)71, plasma CoQ10 showed a gradual increase from baseline when 
increasing doses of CoQ10 were administered. Although the increase of plasma CoQ10 from 
baseline was much greater when high doses (300 to 3000 mg) of CoQ10 were given, the 
increase in plasma CoQ10 per 100 mg of CoQ10 ingested was much lower compared to 
when lower doses (30 to 300 mg) were administered. This may indicate a decrease in the 
efficacy of absorption when higher doses of CoQ10 are given.71 The differentiation between 
low/moderate dose and high doses of CoQ10 in this study were, however, arbitrary. The 100 
mg difference between the CoQ10 dose in the study of Caso (2007)70 and the study of Young 
et al (2007)27 may also not have been sufficient to motivate the different results regarding 
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symptoms of myopathy. Similarly, a study duration of 30 days versus 12 weeks in the studies 
of Young et al (2007)27 and Caso (2007)70 respectively may also not have had an effect on 
the results. In the study of Hosoe (2007)139, 90 mg, 150 mg and 300 mg of CoQ10 were 
administered to participants for 4 weeks. Although plasma CoQ10 levels increased more in 
the participants given higher doses of CoQ10 (150 and 300 mg), all participants‘ plasma 
levels reached a plateau on day 14. Although dose and duration of supplementation may 
have an effect on the CoQ10 plasma concentration, it is unclear whether they would affect 
improvement in myopathic symptoms - dose-response studies are thus yet to be explored to 
establish relevance.   
Results from the studies of Kelly et al (2005)180 and Fedacko (2009)181 were not included in 
the review as the full-text report was not available. The study of Kelly et al (2005)180 was 
reported in a poster abstract and was not published, whereas the study of Fedacko (2009)181 
was published in the Atherosclerosis Supplement, but a full text of the report could not be 
retrieved. The data obtained from the abstracts of these studies, however, appeared 
supportive of CoQ10 for statin-induced myopathy. The study of Kelly et al (2005)180 is similar 
to Caso (2007)70 as it also used 100 mg CoQ10 for 30 days. The study also reported a 
significant improvement in pain after supplementation with CoQ10. The study of Fedacko 
(2009)181 reported that symptoms of myopathy significantly improved in the CoQ10 group 
after 3 months of intervention with CoQ10, however, the CoQ10 dosage was not given in the 
study abstract. This should act as encouragement for authors to publish data from RCTs in 
order to attempt synthesis of data in future. If these studies were included in the systematic 
review, conclusions may have been different and most likely in favour of CoQ10 for statin-
induced myopathy.  
At this stage, no treatment mechanism for statin-induced myopathy exists besides cessation 
of statin treatment, followed by a change in statin type and/or dose relative to patient-to-
patient tolerability. Because CoQ10 is a natural supplement, is not harmful and does not 
interfere with the efficacy of statins, it may be routinely used by patients who are able to afford 
it. In the ideal clinical setting, the medical professional (physician/dietitian) will provide the 
patient with an informed choice regarding the use of supplements such as CoQ10. However, 
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many patients will purchase CoQ10 without consulting with a medical professional, thus 
CoQ10 will continue to be used despite the lack of research-based evidence.  
4.2. DIFFERENCES BETWEEN THE STUDIES  
It is difficult to compare results from the study of Caso (2007)70 and Young et al (2007)27 as 
the methodology and study outcomes differed. The following differences were found, which 
were thought to introduce heterogeneity: 
The study of Young et al (2007)27 is placebo-controlled, whereas the study of Caso (2007)70 
uses a similar antioxidant, Vitamin E as the comparator. In this study, Vitamin E was taken at 
400IU once daily for 30 days. Although a placebo is the golden standard when conducting a 
RCT, Vitamin E as a control was valuable as it was chosen to control for the antioxidant 
actions of CoQ10. Both supplements were also similar in appearance. In the study of Mancini 
et al (2011)46, Vitamin E was implicated as an emerging therapy for the treatment of statin-
induced myopathy. However, the study of Caso (2007)70 was the only study in which Vitamin 
E was used for this purpose, and results showed that it had no value for pain relief.70 Whether 
Vitamin E has any other properties that may motivate its use for pain relief is unknown. A 
Vitamin D deficiency is related to non-statin related muscle disease,69 which may be why it 
has been recommended as a possible treatment mechanism. However, no such data exists 
for Vitamin E.  
 
The other sources of heterogeneity may have included the different dose and type of statin/s 
used by study participants. In the study of Caso (2007) 70, dose and type of statins were not 
standardized – simvastatin, atorvastatin, pravastatin as well as lovastatin were used (Table 
3.3) in low (10 to 20 mg/day) as well as high (>40 mg) doses (Table 3.4). In the study of 
Young et al (2007)27, only simvastatin was used by participants and was titrated from a 
starting dose of 10 to 20 mg/day and then to 40 mg/day at 4-weekly intervals. The 
ACC/AHA/NHLBI clinical advisory board implicates high-dose statin therapy as a risk factor 
for myopathy. The type of statin and the extent of lipid reduction are among other proposed 
factors.52,68 Although one of the inclusion criteria for the review was that participants already 
experience symptoms of myopathy at baseline, the above risk factors may have influenced 
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individual patient recovery. Titration of low-dose statin therapy (10 to 20 mg/day) to a higher 
dose (40 mg/day) may have been a cause for the increase in pain experienced by the study 
participants in both the intervention and control groups in this study. 
The measurement tools for myopathy also differed between the studies. To date, a 
standardized measurement tool specific to myopathy does not exist, thus the studies of Caso 
(2007)70 and Young et al (2007)27 adapted tools that are used to assess pain. These tools 
were the BPI and VAS. Although both tools are well researched, the evidence is not validated 
in myopathy. The tools do not account for minor symptoms of myopathy such as muscle 
cramps, fatigue/tiredness and weakness, symptoms that are more common than pain in most 
statin users. Minor symptoms may occur in the absence of CK elevation, which was seen in 
the study of Young et al (2007)27, where no correlation between the pain score and plasma 
CK concentration before or after the intervention was found. The BPI and VAS were also 
found to differ in terms of what they measured, how often they were applied, as well as the 
scales they used (Table 3.5), which made it very difficult to compare the results obtained from 
the two studies.  
The study of Caso (2007)70 did not measure plasma or intramuscular CoQ10. Although 
CoQ10 supplementation had a positive response in the study population, the method of 
administration of CoQ10 and whether it was efficiently absorbed was unclear. The study of 
Young et al (2007)27 measured plasma CoQ10, but the method of administration of CoQ10 
was also unclear. Factors such as whether the supplement was taken with a meal containing 
fat to aid absorption, whether the supplement was a capsule/powder/other, and at what time 
of the day the supplement was taken may help ensure that the supplement is bioavailable. 
4.3. OVERALL COMPLETENESS AND APPLICABILITY OF THE EVIDENCE 
The two included RCTs are complete in methodological design, but the evidence would be 
stronger if they both had larger study populations. The total number of participants between 
the two RCTs is 76, which is a small number given the statistics of CVD patients. Because 
only two RCTs met the inclusion criteria, assessment of publication bias could not be 
accomplished. There were two RCTs on CoQ10 and statin-induced myopathy that could not 
Stellenbosch University http://scholar.sun.ac.za
  - 70 - 
be included in the review as no full texts of the reports could be sourced, which means that 
valuable data may have been excluded. Both of these abstracts are supportive of CoQ10, 
whereas the two RCTs included in the review have conflicting results/conclusions, so no 
recommendations can made for clinical practice based on the available evidence. A more 
concerted effort could have been made to contact the authors of the said abstracts, however 
time was limited. The measurement of myopathy was not standardized, and results between 
the two included RCTs were expressed in means with SDs as well as medians with IQRs, 
thus a meta-analysis could also not be performed as planned. The primary outcome of the 
review, the improvement of symptoms of myopathy, is poorly researched. Even if the 
inclusion criteria were less rigid, for example if statin use could have been discontinued at the 
time of the intervention or if the participants were not restricted to adults, it appears that still 
only the two RCTs would be included. The only other study that explored CoQ10 for statin-
induced myopathy is that of Langsjoen (2005)172 which is a prospective analysis. In this study, 
the prevalence of patient symptoms of myopathy on initial visit and on most recent follow-up 
demonstrated a decrease in fatigue from 84% to 16%, and myalgia from 64% to 6%.  
4.4. QUALITY OF THE EVIDENCE 
The five factors that decrease the quality level of a body of evidence are:  
 limitations in the design and implementation,  
 indirectness of evidence,  
 unexplained heterogeneity or inconsistency of results,  
 imprecision of results and  
 a high probability of publication bias.  
Because a meta-analysis could not be performed as planned, risk of bias could not be 
determined across studies, and were thus reported separately. The study of Caso (2007)70 
and Young et al (2007)27 have a low risk of bias as all applicable domains of methodology are 
classified as having a low risk (Table 3.9 and 3.10). The only clear limitation for both studies 
is that they include only a small number of participants. 
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4.5. POTENTIAL BIASES IN THE REVIEW PROCESS 
A funnel plot could not be used to detect potential biases in the review process as less than 
10 studies were included in the review. When there are fewer studies, the power of the test is 
too low to distinguish chance from real asymmetry.  
Hand searches of reference lists were one of the methods used to search for studies for 
inclusion in the review. The abstracts of Kelly et al (2005)180 and Fedako (2009)181 were 
sourced in this manner. The scanning of reference lists may produce a biased sample of 
studies, thus causing citation bias. Motivation for citing certain articles may include 
persuasiveness to advocate a personal opinion or to justify a point of view. Over-citation of 
supportive versus unsupportive studies is not present in this review as only two studies were 
included, of which one is supportive of CoQ10, and the other is unsupportive. Electronic 
searches were conducted with language restrictions – all non-English studies were thus 
excluded from the review - language bias may thus have been present.  
4.6. AGREEMENTS AND DISAGREEMENTS WITH OTHER STUDIES OR REVIEWS 
The results of this review are consistent with those in a previous systematic review on CoQ10 
for statin-induced myopathy by Marcoff (2007)173. It was anticipated that more RCTs on 
CoQ10 for statin-induced myopathy would have been published since this review, which was 
published 5 years ago. Although the review also identified Caso (2007)70 and Young et al 
(2007)27, it did not discuss Kelly et al (2005)180 which was presented as a poster abstract in 
2005. The only more recent data was found in the abstract of the study of Fedacko (2009)181. 
The review of Reinhardt (2012)186 was recently published. It discussed strategies for avoiding 
the discontinuation of statin therapy due to muscular adverse effects. The review searched 
MEDLINE and the Cochrane Central Register of Controlled Trials from inception through to 
April 2010 using a similar search string, however also including terms for ‗alternative 
strategies‘ (i.e. Vitamin D, ubiquinone, red rice yeast, red yeast rice, alternate dosing, or 
alternate dosage). No language restrictions were implemented. The review was not restricted 
to RCTs – it required that the studies included a systematic method of patient selection and 
that they addressed the outcomes of a strategy to maintain the use of a statin in patients with 
Stellenbosch University http://scholar.sun.ac.za
  - 72 - 
prior muscle-related intolerance. Because studies were not RCTs, a meta-analysis was not 
planned. The review also did not focus solely on CoQ10 as an intervention – CoQ10 was, 
however, one of the strategies described in 3 out of 16 of the review‘s selected articles. The 3 
articles described are the studies of Caso (2007)70, Young et al (2007)27 and Kelly et al 
(2005)180. Reinhardt (2012)186 reported that the differences in study design between these 3 
studies (e.g., the use of a washout period, the use of vitamin E rather than a placebo in the 
control group) were responsible for the divergent study results and that the evidence 
supporting the use of CoQ10 for statin-induced myalgia was limited by inclusive results 
published thus far. Other differences between the studies that may also have contributed to 
the divergent results were the different doses and types of statins used by the study 
participants, as well as the different measurement tools for myopathy. Reinhardt (2012)186 
concluded that the limited and conflicting evidence on CoQ10, coupled with the additional 
costs, meant that CoQ10 was probably best recommended only for patients similar to those 
for whom vitamin D may be appropriate, i.e. in patients with mild symptoms who are enrolled 
in a well-monitored trial. However, only one clinical trial was identified for Vitamin D by Ahmed 
et al (2009) 187, which was given a poor bias assessment (poor being defined as the study 
either having no control group or having a control mechanism but was deemed to have 
severe methodological shortcomings).  
 
The exact pathophysiology of statin-induced myopathy has also not yet been confirmed. The 
review of Marcoff (2007)173 highlights the insufficiency of evidence to implicate a CoQ10 
deficiency as the cause of statin-induced myopathy. This is supported by other studies where 
the efficacy of CoQ10 is hypothesised due to a decreased serum CoQ10 in statin users.31 
There remain several possible causes of statin-induced myopathy as well as numerous 
factors that may increase the risk of myopathy in statin users. This number of confounding 
factors may be the reason/s why funding agencies and pharmaceutical companies are not 
investing their time and money in further investigating whether CoQ10 depletion as a result of 
statin therapy is the cause of myopathy, as well as whether routine CoQ10 supplementation is 
a definitive treatment mechanism.  
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Thus far, no other review on CoQ10 for statin-induced myopathy, besides Thompson 
(2006)52, was identified that raises concern regarding the lack of a standardized measurement 
tool for myopathy. Patient reports of symptoms of myopathy have thus far been subjective, 
and measurement tools not specific to myopathy have been used. In the prospective analysis 
of Langsjoen (2005)172, the measurement tool for myalgia in study participants was not 
stipulated. However, participants were tested for proximal muscle weakness (details not 
stipulated) and CK levels. The only other studies that used the same/similar tools to those 
used by the study of Caso (2007)70 and Young et al (2007)27 (the BPI and VAS) used the 
tools to diagnose pain in mostly cancer patients and for reasons relating to palliative care. 
The study of Koumis (2004)31 discusses the benefits of statin therapy and that they outweigh 
the risk of statin-induced myopathy. Although statins are far more extensively researched, 
their side effects may be underreported and thus may be more commonly seen in clinical 
practice. This warrants high-quality research to explore treatment mechanisms for this 
adverse effect. One should keep in mind that although the prevalence is low, statin-induced 
myopathy can result in fatal rhabdomyolysis if left untreated.  Although rare, rhabdomyolysis 
can be life-threatening and may result in permanent kidney damage, muscle fatigue and 
pain.188 These long-term effects as well as the mild symptoms of statin-induced myopathy 
(namely muscle weakness and fatigue, which mirror the long term effects of rhabdomyolysis), 
may have an effect on patient quality of life and thus everyday functioning. 
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CHAPTER 5:  AUTHOR’S CONCLUSIONS 
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Based on the two studies included in the review, there is inconclusive evidence to support the 
recommendation of CoQ10 supplementation for statin-induced myopathy, especially in 
developing countries considering the high cost of such therapy. More RCTs on the efficacy of 
CoQ10 as a treatment for statin-induced myopathy are, however, warranted to establish 
whether CoQ10 should form a part of future management guidelines. Researchers are also 
encouraged to publish results of RCTs on CoQ10 and statin-induced myopathy, regardless of 
whether the data support the use of CoQ10 in clinical practice or not. 
5.1. IMPLICATIONS FOR PRACTICE 
 CoQ10 is a natural nutritional supplement. If supplementation is advised for patients with 
statin-induced myopathy, the typical doses remain between 60 and 200 mg daily, which 
may serve as a guideline in clinical practice.  
 No adverse effect directly related to CoQ10 supplementation in healthy humans exists. 
CoQ10 supplements are available without prescription and can thus be can used without 
medical supervision. 
 Adverse effects of CoQ10 in chronic care are very rare and mostly apparent when doses 
above 1200 mg/day (the OSL) of CoQ10 are supplemented. If a patient is supplemented 
above this level, be aware of gastrointestinal symptoms (loss of appetite, abdominal pain, 
nausea and vomiting), central nervous system changes (dizziness, photophobia, irritability 
and headaches), as well as itching, rash, fatigue and flu-like symptoms. 
 CoQ10 supplements can be taken as an adjunct to statin therapy without affecting their 
cholesterol-lowering effects. 
 Many factors that may increase a patient‘s risk to statin-induced myopathy have been 
suggested. To date, the statin dose appears to be the most common risk factor. 
 Other popular drugs also deplete or interfere with the biosynthesis of coenzyme Q10. 
Blitznakov (2002)189 cited a roster that includes a list of 49 drugs that may have this 
effect. In these patients, plasma and/or intramuscular CoQ10 levels may be 
lower/depleted at baseline. 
 Cost remains important and should be discussed with each patient individually. Statin 
therapy should continue when/if CoQ10 supplements are taken, a cost that is already a 
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burden to most CVD patients. Some practical recommendations to enhance the cost-
benefit relationship of routine supplementation would be to: 
 Advise the patient to purchase a bioavailable form of CoQ10. Thus far, a solubilized form 
of CoQ10 remains the most bioavailable supplement.   
 Encourage the patient to take the CoQ10 supplement with a meal that includes healthy, 
unsaturated fats to enhance the absorption of the supplement as it is lipophilic.43 
Implications for practice from the study of Thompson (2006)52 are reemphasized: 
 Statin-induced myopathy may not be accompanied by CK elevation or pain. The 
physician should be aware of minor patient complaints such as muscle weakness and 
cramps, which may affect patient quality of life. 
 A validated measurement instrument for symptoms of myopathy needs to be developed. 
5.2. IMPLICATIONS FOR RESEARCH 
Many narrative reviews exist regarding the use of CoQ10 for statin-induced myopathy. Larger 
RCTs are warranted to investigate the effect of CoQ10 on statin-induced myopathy to provide 
more conclusive results and implications for medical practice. Specific attention should be 
given to outcomes measured such as minor symptoms of myopathy (muscle complaints), and 
a standardized measurement tool should be developed and validated for use in future 
research to measure these outcomes. Major symptoms (CK elevation) of myopathy as well as 
plasma and intramuscular markers of CoQ10 should continue to be measured and reported 
as mean (SD) for comparison with other studies in future systematic reviews. When more and 
larger RCTs are available on CoQ10 and statin-induced myopathy, meta-analysis can be 
reattempted to provide for more conclusive evidence and thus to assist with medical 
management guidelines. 
Stellenbosch University http://scholar.sun.ac.za
  - 77 - 
Guidelines for future research: 
 To develop and validate a measurement tool which explores the different symptoms and 
signs specific to myopathy, including plasma CK elevation. 
 Conduct and publish high-quality RCTs, which will entail larger study populations. 
 Race/ethnicity, gender and age (elderly) may affect the patients‘ risk to myopathy, so 
these groups should be investigated separately. 
 CoQ10 should be taken as an adjunct to statin therapy in all future controlled trials – 
discontinuing statin therapy when commencing CoQ10 may be seen as two 
interventions, which may limit applicability of study findings. 
 Only bioavailable forms of CoQ10 should be used as the intervention. Administration of 
the CoQ10 with a meal containing unsaturated (healthy) fats to aid in absorption is 
recommended. 
 Future studies should explore patients‘ dose response to CoQ10 by monitoring 
improvement in the patients‘ symptoms of myopathy with increasing doses. A higher 
dose of CoQ10 will result in higher plasma CoQ10 levels. 
 The type of statin as well as the dose of statin should be standardized across study 
participants so as to avoid introducing heterogeneity. It is recommended that the type 
and dose of statin be stratified to determine whether a certain statin dose may require a 
certain CoQ10 dose to improve symptoms of myopathy. 
 More studies are required that measure the relationship between intramuscular and 
plasma CoQ10 concentrations. No data exists that may implicate a deficient 
intramuscular CoQ10 as the cause/one of the causes for statin-induced myopathy. 
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ADDENDUM A – Data extraction form 
 
Notes: 
_________________________________________________________________________________________________
_________________________________________________________________________________________________
_________________________________________________________________________________________________
_________________________________________________________________________________________________
_________________________________________________________________________________________________
________________________________________________________________________________ 
 
 
Form no.:  
Revision date:  
Source: 
Study ID (created by review author) – last 
name of the first author & year  
 
 
Report ID (created by review author)  
 
Review author ID number  
 
Citation & contact details (email & phone 
number) 
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Eligibility: 
Confirm eligibility & 
reasons 
(tick the check-list) 
Human subjects  English 
language study 
 
 
Statin therapy is 
being taken in 
any dose 
 
 
Effectivity of 
CoQ10 is 
measured by 
Plasma CK & 
improved 
myopathic 
symptoms 
 
Study is a RCT 
 
There is a 
control group 
Participants are 
all experiencing 
myopathic 
symptoms 
The control is a 
placebo, similar 
antioxidant or no 
intervention 
CoQ10 is used 
with their usual 
medication 
(including 
statins) 
The mean age 
of participants 
are between 18 
and 64.99 years 
Or reason/s for exclusion 
(tick the check-list) 
CoQ10 is used in 
combination with other 
supplemental medication 
There is no control group Study is not a RCT 
 
 
This is an Animal study No full text is available Participants have clinical 
evidence of other serious 
medical conditions (Hepatic, 
Renal, Endocrine Disease) 
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Methods: 
Study design  
Total study duration 
(weeks) 
 
Country 
 
 
Setting Acute care facility (e.g. 
hospital) 
 
 
 
Chronic care facility (e.g. 
nursing home) 
General practice 
(outpatients) 
Diagnostic criteria of myalgia (how 
was myalgia determined) 
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Participants receiving CoQ10 (study group): 
Total number  
Age (mean and SD)  
Gender (indicate number) e.g 
Male 10, female 12 
Male  Female  Not indicated 
Ethnicity (indicate numbers as 
well) 
Black Caucasian Indian Coloured Other (specify): Not indicated 
 
 
Participants receiving the control (control group): 
Total number  
Age (mean and SD)  
Gender (indicate numbers) Male  Female  Not indicated 
Ethnicity (indicate numbers as 
well) 
Black Caucasian Indian Coloured Other (specify): Not indicated 
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Intervention details: 
Specific intervention 
CoQ10 
supplementation 
type/name 
 
Comparator group type 
(e.g. placebo/vitamin E) 
 
 
Route of 
administration 
Dose (amount) 
Frequency of delivery 
(/day) 
Duration of intervention 
(weeks) 
CoQ10 
supplementation 
Oral 
   
Other (specify): 
 
 
 
 
 
Comparator  
Oral 
   
Other (specify): 
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Outcomes: 
Primary Outcomes and time points 
Collected 
 
1. 
2. 
3. 
4. 
5. 
Reported 
 
1. 
2. 
3. 
4. 
5. 
Secondary Outcomes and time points 
Collected 
 
1. 
2. 
3. 
4. 
5. 
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Reported 
 
1. 
2. 
3. 
4. 
5. 
 Outcome definition (diagnostic method, name of scale, definition of threshold or 
type of behavior) 
Unit of 
measurement  
Intensity and/or 
frequency of myopathic 
pain 
 
  
Plasma creatine kinase 
(CK) 
 
  
Intramuscular CoQ10 
 
  
Plasma CoQ10 
 
  
Adverse effects of CoQ10 
(list, if any) 
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Results: 
Number of participants allocated to each intervention group 
CoQ10 supplementation  
Comparator (placebo/similar antioxidant/no intervention)  
Participants receiving CoQ10 (study group): 
 
Sample size for each outcome of 
interest  
Number of missing 
(withdrawal/dropout) participants for 
each outcome of interest  
Intensity and/or frequency of 
myopathic pain 
  
Plasma creatine kinase (CK)   
Intramuscular CoQ10   
Plasma CoQ10   
Adverse effects of CoQ10   
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Participants receiving the control (control group): 
 
Sample size for each outcome of 
interest  
Number of missing 
(withdrawal/dropout) participants for 
each outcome of interest  
Intensity and/or frequency of myopathic 
pain 
  
Plasma creatine kinase (CK)   
Intramuscular CoQ10   
Plasma CoQ10   
Adverse effects of CoQ10   
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Summary data for each intervention group 
1. Participants receiving CoQ10 (study group) 
 Baseline 
Measurement 
Final  
Measurement 
Continuous data Mean SD Mean SD 
Plasma creatine kinase (CK)     
Intramuscular CoQ10     
Plasma CoQ10     
Myopathic pain     
Dichotomous data 
YES NO NOT 
INDICATED 
YES NO NOT 
INDICATED 
Adverse effects of CoQ10       
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2. Participants receiving the control (placebo/similar antioxidant/no intervention): 
Continuous data Mean SD Mean SD 
Plasma creatine kinase (CK)     
Intramuscular CoQ10     
Plasma CoQ10     
Myopathic pain     
Dichotomous data 
YES NO NOT 
INDICATED 
YES NO NOT 
INDICATED 
Adverse effects of CoQ10       
Subgroup analyses: 
1. 
2. 
3. 
4. 
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Other/Miscellaneous: 
 
Funding source 
 
 
Key conclusions of study authors 
 
 
 
 
 
Miscellaneous comments from study 
author/s 
 
 
 
 
 
References to other relevant studies 
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Correspondence required 
 
 
 
 
 
 
 
Miscellaneous comments by 
independent reviewer 
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ADDENDUM B – Assessment of risk of bias form 
Domain 
Review Authors’ 
judgment  
Yes=low risk of 
bias 
No=high risk of 
bias 
Description  
Adequate 
sequence 
generation? 
Procedure of allocation 
i.e. randomization 
procedure 
YES   
Describe the method used to 
generate the allocation 
sequence in sufficient detail to 
allow an assessment of whether 
it should produce comparable 
groups. 
NO 
UNCLEAR 
Allocation 
concealment? 
Treatment to be 
allocated is not known 
before patient is entered 
in the study 
 
YES . 
Describe the method used to 
conceal the allocation sequence 
in sufficient detail to determine 
whether intervention allocations 
could have been foreseen in 
advance of, or during, 
enrolment. 
NO 
UNCLEAR 
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Was knowledge of the allocated intervention prevented during the study? 
For participants 
YES  
 
Describe all measures 
used, if any, to blind study 
participants & personnel 
from knowledge of which 
intervention a participant 
received. Provide any 
information relating to 
whether the intended 
blinding was effective. 
NO 
UNCLEAR 
For personnel 
YES  
NO 
UNCLEAR 
Intensity and/or 
frequency of 
myopathic pain 
YES  
 
 
NO 
UNCLEAR 
Plasma creatine 
kinase (CK) 
 
YES  
 
 
NO 
UNCLEAR 
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Intramuscular 
CoQ10 
 
YES  
 
 
 
 
Describe all measures 
used, if any, to blind study 
participants & personnel 
from knowledge of which 
intervention a participant 
received. Provide any 
information relating to 
whether the intended 
blinding was effective. 
NO 
UNCLEAR 
Plasma CoQ10 
 
YES  
 
 
NO 
UNCLEAR 
Adverse effects of 
CoQ10 
YES  
 NO 
UNCLEAR 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
  - 118 - 
Incomplete outcome data addressed? *see data from page 9 & 10 of this form 
Participants receiving CoQ10 (study group): 
Intensity and/or 
frequency of 
myopathic pain 
 
YES  
 
 
Describe the 
completeness of outcome 
data for each main 
outcome, including 
attrition and exclusions 
from the analysis: 
1. State whether attrition 
and exclusions were 
reported, 
2. The number excluded 
(compared with the total 
randomised participants), 
3. Reasons for 
attrition/exclusions where 
reported, and 
4. Any re-inclusions in 
analyses performed by 
the review authors. 
NO 
NOT APPLICABLE 
Plasma creatine 
kinase (CK) 
 
YES  
NO 
NOT APPLICABLE 
Intramuscular CoQ10 
 
YES  
 
 
NO 
NOT APPLICABLE 
Plasma CoQ10 
 
YES  
 
 
 
NO 
NOT APPLICABLE 
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Adverse effects of 
CoQ10 
YES  
 
 
NO 
NOT APPLICABLE 
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Participants receiving the control (placebo/similar antioxidant/no intervention): 
Intensity and/or 
frequency of 
myopathic pain 
 
YES  Describe the 
completeness of 
outcome data for each 
main outcome, including 
attrition and exclusions 
from the analysis: 
1. State whether attrition 
and exclusions were 
reported, 
2. The number excluded 
(compared with the total 
randomised participants), 
3. Reasons for 
attrition/exclusions where 
reported, and 
4. Any re-inclusions in 
analyses performed by 
the review authors. 
NO 
NOT APPLICABLE 
Plasma creatine 
kinase (CK) 
 
YES  
 
 
NO 
NOT APPLICABLE 
Intramuscular CoQ10 
 
YES  
 
 
NO 
NOT APPLICABLE 
Plasma CoQ10 
 
YES  
 
 
NO 
NOT APPLICABLE 
Adverse effects of 
CoQ10 
YES  
 
 
NO 
NOT APPLICABLE 
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Free of selective 
outcome reporting? 
 
YES  State how the 
possibility of 
selective outcome 
reporting was 
examined by the 
review authors, and 
what was found. 
NO 
Free of other sources of bias? 
Was Intention To 
Treat (ITT) analysis 
of data conducted? 
YES 
 
Comments: 
NO 
 
Other  
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